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This paper is a chronological supplement to our earlier publication, "A Carcinogenic Potency Database
of the Standardized Results of Animal Bioassays." We report here results of carcinogenesis bioassays
published in Technical Reports of the National Cancer Institute/National Toxicology Program between
July 1980 and December 1982, and the general literature between July 1981 and December 1982. This
supplement includes results of280 long-term, chronic experiments of 114 test compounds, and reports the
same information about each experiment in the same plot format as the earlier paper: e.g., the species
and strain oftest animal, the route and duration ofcompound administration, dose level and other aspects
of experimental protocol, histopathology and tumor incidence, TD50 and its statistical significance, dose
response, author's opinion about carcinogenicity, and literature reference. While a number ofappendices
are provided to facilitate use of this supplement, we have not duplicated here the material published
earlier. Instead, we refer the reader to the earlier publications (Peto et al. and Gold et al.) for a thorough
description of the numerical index of carcinogenic potency (TD50), a guide to the plot of the database,
and a discussion of the sources of data, the rationale for the inclusion of particular experiments and
particular target sites, and the conventions adopted in summarizing the literature. For 44 of the 114
chemicals reported in this second plot, results of earlier experiments are also given in the first plot; since
only 1981-1982 results are reported here, the first plot is required for these repeated compounds. In this
paper we also give corrections for errors that appeared in the earlier publication.
Background
The Carcinogenic Potency Database of long-term,
chronic carcinogenesis bioassays was first presented in
two papers in 1984, Peto et al. (1) and Gold et al. (2).
Peto et al. (1) described our numerical index of carcin-
ogenic potency, the TD50, and the statisticalprocedures
adopted for estimating it from experimental data.
Briefly, TD50 may be defined as follows: for a given
target site(s), ifthere are no tumors in control animals,
then TD50 is that chronic dose rate in milligrams per
kilogram body weight/day which would induce tumors
in halfthe test animals at the end ofa standard lifespan
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forthe species. Since the tumor(s) ofinterest often does
occur in control animals, TD50 is more precisely defined
asthatchronicdoseratewhichwillhalvetheprobability
of remaining tumor-free throughout the standard life-
span of the species.
Gold et al. (2) presented a plot of the Carcinogenic
Potency Database with an accompanyingguide describ-
ing the contents, field by field, as well as a discussion
of the sources of data, the criteria for the inclusion of
particular experiments and particular target sites, and
the conventions adopted in summarizing the literature.
We have developed the Carcinogenic Potency Database
in an effort to improve the use of animal bioassay data
in both the study of chemical carcinogenesis and the
estimation of the potential health risks of chemicals to
humans. The database quantifies and standardizes a
very diverse body ofliterature, organizes it systemat-
ically, and applies an index ofcarcinogenic potency, the
TD50, to the results ofexperiments on hundreds oftestGOLD ET AL.
compounds. The range of TD50 values for carcinogens
in the database is more than 10 million-fold (2).
The plot of the database provides a variety of infor-
mation about each experiment, including: the species,
strain, and sex of test animal; features of the experi-
mental protocol such as route of administration, dura-
tion of dosing, dose level(s) in mg/kg body weight/day,
and duration of experiment; histopathology and tumor
incidence; carcinogenic potency and its statistical sig-
nificance; shape of the dose response curve; author's
opinion as to carcinogenicity; and literature reference.
A word of caution is necessary about the limitations of
the database. We have included only long-term tests of
individual compounds which fit a set of criteria com-
patible with calculating potency; many animal cancer
tests are excluded. Moreover, we have not attempted
to evaluate whether or not a compound is a carcinogen;
rather, we report the published opinions of the inves-
tigators whose datawepresent, aswellasthestatistical
significance of the TD50 calculated from their results.
Further discussion of the criteria for the database and
the limitations can be found in Gold et al.(2).
Supplement to the Carcinogenic
Potency Database
In this paper we present a chronological supplement
to the plot, which updates the results for the literature
published through December 1982. Rather than repeat
the material published earlier, we refer the reader to
the complete discussion and the plot in the earlier pub-
lication (2). The format of this new plot is identical to
that of the first plot. It is our intention that the two
plots be used together and that readers who are not
familiar with the database will read the earlier papers
first.
The plot ofthe database below includes results of280
long-term, chronic experiments with 114 chemicals. It
presents results for 32 compounds from Technical Re-
ports of the National Cancer Institute/National Toxi-
cology Program (NCI/NTP) published between July
1980 and December 1982, as well as results for 82 com-
poundspublished inthegeneral literature betweenJuly
1981 and December 1982. The database as presented in
the previous publication (2) covered the literature and
the NCI/NTP Technical Reports published prior to
these dates and included 2944 experiments of 770 test
compounds. Results for several experiments that were
published during the time frame ofthis supplementary
plot were included in the first plot because of our on-
going analyses. We have not repeated those results
here.
Experiments in rats, mice, hamsters, and rhesus
monkeys are reported here for 114 compounds repre-
senting a variety of chemical classes (e.g., aromatic
amines, nitroso compounds, hydrazines) with a variety
ofuses. Some are naturally occurring substances which
are constituents of foods (e.g., caffeine, quercetin dih-
ydrate, allyl isothiocyanate); food additives (e.g., bu-
tylated hydroxytoluene, cinnamylanthranilate, gum ar-
abic); industrial compounds (e.g., vinyl chloride,
ethylene oxide, 1,2-propylene oxide); and drugs (e.g.,
phenacetin, phenobarbital, norlestrin). Ofthe 114chem-
icals, 44 were also included inthe firstplot, and we have
flagged these in the plot below with a triple asterisk
(***) after the chemical name. For some of these sub-
stances only one experiment is reported here, but large
numbers of experiments were previously reported (2),
e.g., 2-acetylaminofluorene and isoniazid. We have not
duplicated the earlier results here, and thus, for com-
plete results on these chemicals, both publications are
necessary.
As in the first database, the TD50 values forthe NCI/
NTP bioassays have been estimated using full lifetable
information. For the TD50 values from the general lit-
erature the estimates use the final proportions of ani-
mals with tumors, since only this summary information
is consistently published (3). The TD50 values for the
compounds in this supplementary plot fall within the
range of values reported earlier [Figure 1 in (2)]. In a
few cases no TD50 could be calculated because all dosed
animals had the tumor of interest, and only summary
incidence data were available (4).
Theappendicesprovidethe sametypesofinformation
as given in the earlier publication and are given the
sameappendixnumbers. Appendix 1 listsalphabetically
the compounds included in this plot and their common
synonyms; Appendix 2 provides the same information
ordered by Chemical Abstracts Service (CAS) Registry
number. The nextseveral appendices provide codes and
definitions required for using the plot: strains of test
animal (Appendix 3); routes of administration (Appen-
dix 4); site (Appendix 5); histopathology (Appendix 6);
notecodes (Appendix 7); dose-response curve symbols
(Appendix 8); reference codes (Appendix 9); NCI/NTP
bioassays evaluated as inadequate (Appendix 10); and
species (Appendix 11). Appendices 12 and 13 give full
bibliographic information for all experiments reported
in this plot: the bibliography for the general literature
(Appendix 12); and a list of the NCI/NTP Technical
Reports (Appendix 13).
We are continuing to update the Carcinogenic Po-
tency Database with papers published after 1982, and
are alsoattemptingto addearlierpaperswhichwe over-
looked in our literature search. Therefore, we would
appreciate information about anytestswhichthereader
notices are missing.
Analyses of the Database
Our group has been using the results ofthe database
published in Gold et al. (2) for several analyses, some
still in progress. The good correlation of carcinogenic
potency found between rats and mice and some tauto-
logous aspects of this comparison have been examined
using the chemicals tested by the NCI/NTP Bioassay
Program (4). Two methods for estimating carcinogenic
potency (TD50) from animal bioassays have been com-
pared, one based on lifetable data and one based on
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summary incidence data (5). We have described the po-
tencies ofcompounds which induce tumors at particular
target sites in rats and mice and have examined other
indicators ofa chemical's hazard including: whether tu-
mors were induced at more than one site in a single sex-
species group oftest animal, whether tumors may have
causedthedeathoftheanimalorwerefoundatsacrifice,
and whethermetastases ofinducedtumors occurred (6).
We have identified "near-replicate" carcinogenesis
bioassays by selecting from the entire database those
cases in which a single compound was tested more than
once in a particular species, strain, and sex of rodent
bythe sameroute ofadministration, andhave examined
the extent of reproducibility of the results for these
tests (7).
Other work in progress using the results ofthe Car-
cinogenic Potency Database includesadescriptionofthe
extent to which compounds tested for carcinogenicity
are positive-using various data sources, routes of
administration, and frequency oftesting; the predictive
value oftarget sites in rats and mice is also examined.
Various methods are being investigated for summariz-
ing the potency ofa single compound when several ex-
periments have been conducted and a number of dif-
ferent TD50 values have been estimated for this same
chemical. We are also exploring methods for comparing
current human exposure levels to a substance, with the
tumorigenic dose rate (TD50) estimated fromthe results
of carcinogenesis bioassays (8).
Errata in the Earlier Publication
Since the earlier publication (2), a few errors have
come to our attention. In three cases the database re-
ports results for a single experiment as two different
experiments because slightly different information had
been published in two separate papers. The following
corrections should be made:
For ethylene thiourea, lines 1270 and 1271 are one
experiment in female Charles River CD rats, and lines
1272 and 1273 are one experiment in males.
For N-nitrosodiethylamine, lines 2027 and 2030 are
one experiment in female Fischer F344 rats.
For nitrosopyrrolidine, lines 2087 and 2088 are one
experiment in female MRC rats, and lines2088and 2089
are one experiment in males.
In one other case, carrageenan (acid-degraded), two
separate experiments are reported in Sprague-Dawley
rats-one in which the compound was administered by
gavage and one in the diet. However, the plot incor-
rectly assigned only one experiment number, line 482,
to the two of them.
In the text, page 17, column 2, line 35, the number
5.55 mg/kg body weight/day should be 6.93 mg/kgbody
weight/day.
We would appreciate hearing about any additional
errors which are discovered as the database is used.
We wish to thank Melody Cheng and Catherine Wright for their
assistance and Suzanne Kuehl for technical support.
This work was supported by NIEHS/DOE InteragencyAgreement
222-Y01-AS-10066 through the Lawrence Berkeley Laboratory.
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Plot of the Carcinogenic Potency Database
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
ACETALDEHYDE NETHYLFORNYLHYDRAZONE
N N f swa gav Lun mix 12.25 es
a N f swa gav Lun ad. 12.25 es
b N f swa gav Lun adc 12.25 cs
c N f swa gav for mix 12.25 cs
d N f swa gav for sqp 12.25 cs
* N f swa gav cLi mix 12.25 es
f N f swa gav cLi sqc 12.25 cs
g N f swe gav Liv hpt 12.25 cs
2 N m swa gav pro mix 52w79 as
a N m swa gav pro sqc 52w79 as
b N awea gav pro fbs 52w79 es
c N m swa gav Liv hpt 52w79 as
d N m swe gav Lun ad. 52w79 es
* N m ewa gav Lun mix 52w79 es
ACETOXINE
3 R f mrw wat Liv mix 18m30 a
a R f mrw wat liv hpa 18m30 a
b R f mrw wat Liv hem 18m30
c R f mrw wat tba mix 18m30 a
4 R a mrw wat Liv mix 18m26 a
a R m mrw wat Liv hpa 18m26 a
b R m mrw wat Liv hem 18m26 a
c R m mrw wat tba mix 18m26 a
TD50 2Tailpvl
DR AuOp
l. : 1ug . : 10 .: 100.:1.g.:10. :100.:Ig. :10























2-ACETYLANINOFLUORENE*** lOOng .. : lug.:10. :100.l. :g.:10. :100.. : g :10











6 N f b6c *at TBA NXB 24m24
a N f b6c eat Liv NXB 24m24
b N f b6c sat Lun NXB 24m24
7 N m b6c sat Liv hpa 24m24
a N m b6c sat TBA NXB 24m24
b N m b6c eat Liv NXB 24m24
c N m b6c sat Lun NXB 24m24
8 R f f34 sat adr coa 24m24
a R f f34 cat TBA NXB 24m24
b R f f34 sat Liv NXB 24m24
9 R m f34 eat TBA NXB 24m24
a R m f34 eat Liv NXB 24m24
ALLYL ISOTHIOCYANATE
10 f b6c gev TBA NXB 24m24
a N f b6c gav liv NXB 24m24
b f b6c gav Lun NXB 24m24
11 m b6c gav Lun a/c 24m24
a N m b6c gav TBA NXB 24m24
b N b6c gav Liv NXB 24m24
c N b6c gav lun NXB 24m24
12 R f f34 gav cub fbs 24m24
a R f f34 gav TBA NXB 24m24
b R f f34 gav Liv NXB 24m24
13 R m f34 gav --- NXA 24m24
a R m f34 gav --- ut l24m24 e
b R m f34 gav ubL tpp 24m24
c R m f34 gav TBA NXB 24m24
d R m f34 gav Liv NXB 24m24
2-ANINO-4- (5-NITRO-2- FURYL)THIAZOI
14 Rft fis eat for mix 52w68
a R f fis cat for sqp 52w68
b R f fis cat ubL mix 52w68
11-ANINOUNDECANOIC ACID
15 N f b6c cat TBA NXB 24m25 es
a N f b6c sat Liv NXS 24m25 es
b N f b6c cat Lun NXB 24m25
16 N m b6c eat mLy 24m25
a N m b6c cat TBA NXB 24m25 es
b N b6c sat Liv NXS 24m25 as
c N b6c sat Lun NXB 24m25 es
17 R f f34 eat TBA NXB 24m25
a R f f34 sat Liv NXB 24m25
18 R f34 oat NXB NXB 24m25 es
bO0ng .. : lug.:10. :100 :..mg. :10. :100.:Ig..:10
:> no dre P-I.
no dre P-1.
no dre P-1.




#25.89m * P<.03 -
no dre P-1.
no dre P-1.
:> 39.3gm * P<1. -
25.9gm * P<.3













96.0mg * P<.02 c
38.0mg * P<.5
174.mg * P<.2
LE ..:. .lug.:10. :100.. : mg.:10. :100.:Ig. :10
+ . 5.85mg P<.0005+
8.94mg P<.0005
30.3mg P<.003 +
lOOng... . :ug . 10. :100. m : g.:10. :100.:Ig. :10
:> 15.6gm * P<.8 -
37.99m * P<.8
18.8gm * P<.4






+ 833.mg * P<.0005
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RefNum LoConf UpConf Cntrl IDose lInc 2Dose 2Inc
ACETALDEHYDE NETHYLFORMYLHYDRAZONE
1 1267 3.21mg 14.0mg 13/50
a 1267 4.01mg 22.5mg 12/50
b 1267 9.49mg 93.0mg 2/50
c 1267 12.7mg 101.mg 0/44
d 1267 14.0mg 150.mg 0/44
1267 15.6mg 292.mg 0/44
f 1267 17.6mg 3.789m 0/44
9 1267 8.45mg n.s.s. 0/32
2 1267 1.01mg 2.62mg 0/37
a 1267 1.40mg 3.49mg 0/37
b 1267 9.65mg 98.0mg 0/37
c 1267 2.68mg n.s.s. 0/14
d 1267 5.79mg n.s.s. 8/47
* 1267 5.57mg n.s.s. 11/47
ACETOXIME 127-06-0
3 1480 38.2mg n.s.s.
a 1480 38.2mg n.s.s.
b 1480 66.3mg n.s.s.
c 1480 11.3mg n.s.s.
4 1480 5.59mg 30.1mg
a 1480 5.59mg 30.1mg
b 1480 33.4mg n.s.s.




































5 1477 1.13mg n.s.s. 5/8 36.0mg 7/8 Becker;canr,42,3918-3923; 1982
AGAR 9002-18-0
6 c50475 4.42gm n.s.s. 26/50
a c50475 34.9gm n.s.s. 4/50
b c50475 13.7gm n.s.s. 7/50
7 c50475 9.179m 79.19m 0/50
a c50475 5.679m n.s.s. 24/50
b c50475 8.46gm n.s.s. 9/50
c c50475 12.19m n.s.s. 6/50
8 c50475 8.92gm n.s.s. 0/50
a c50475 2.799m n.s.s. 47/50
b c50475 n.s.s. nm..s. 0/50
9 c50475 1.67gm n.s.s. 32/50


































10 c50464 15.1mg n.s.s. 18/50
a c50464 56.1mg n.s.s. 2/50
b c50464 45.8mg n.s.s. 2/50
11 c50464 40.7mg n.s.s. 0/50
a c50464 17.0mg n.s.s. 33/50
b c50464 18.6mg n.s.s. 21/50
c c50464 26.9mg n.s.s. 4/50
12 c50464 61.9mg n.s.s. 0/50
a c50464 10.3mg n.s.s. 42/50
b c50464 92.6mg n.s.s. 0/50
13 c50464 24.1mg n..sa. 2/50
a c50464 25.0mg n.s.s. 2/50
b c50464 39.1mg n.s.s. 0/50
c c50464 8.77mg n.s.s. 38/50















































14 1423 2.49mg 12.7mg 0/10 63.5mg 23/24
a 1423 4.66mg 18.1mg 0/10 63.5mg 21/24











15 c50613 1.76gm n.s.s. 28/50
a c50613 3.839m n.s.s. 7/50
b c50613 4.63gm n.s.s. 2/50
16 c50613 2.09gm n.s.s. 2/50
a c50613 1.209m n.s.s. 30/50
b c50613 1.569m n.s.s. 17/50
c c50613 4.889g n.s.s. 10/50
17 c50613 202.mg n.s.s. 46/50
a c50613 2.109g n.s.s. 5/50
18 c50613 494.mg 1.969m 1/50
926.mg 27/50 1.859m 19/50
926.mg 8/50 1.859m 5/50
926.mg 3/50 1.859m 3/50
854.mg 9/50 1.719m 4/50
854.mg 29/50 1.71gm 18/50
854.mg 18/50 1.71gm 12/50
854.mg 3/50 1.719m 4/50
358.mg 47/50 (716.mg 37/50)
358.mg 5/50 716.mg 6/50









Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
a R m f34 eat liv NXA 24.25 es
b R m f34 eat Liv nnd 24.25 es
c R * f34 eat ubt tcc 24.25 *s
d R m f34 eat mgl fba 24.25 es
* R m f34 eat TBA NXB 24.25 es
f R m f34 eat Liv NXB 24.25 es
TD50 2Tailpvl
DR AuOp
1.109m * P<.002 c
1.29gm * P<.004 c




BENZENEDIAZONIUN TETRAFLUOROBORATE .. :.. lug.:10. :100. : g.:10. :100.. :1g :10
19 H f syg gav Liv hem 90w90 es .> 66.1mg * P<.2
a H f syg gav Liv kcs 90w90 *s 66.1mg * P<.2
b H f syg gav Liv cho 90w90 *s 293..g * P<.9
c H f syg gav Lun tur 90w90 es no dre P-1.
20 H m syg gav Liv hem 90w90 es .> 293.mg * P<.9
a H m syg gav Lun tum 90w90 as no dre P-1.
BENZIDINE.2HCL l1Ong. .... lu . :10. :100. g : .. :10. :100.. : . :10
21 N f cbn iat Liv hpc 60w60 ek . + . 17.9mg * P<.0005+
a N f cbn wat Liv hpa 60w60 ek
22 N f cbn wiat Liv hpc 80w80 e
a N f cbn wat Liv hpa 80w80 e
23 N m cbn wat liv hpa 60w60 *k
a N m cbn wat Liv hpc 60w60 ek
24 N m cbn wat liv hpc 80w80 e
a N m cbn wat Liv hpa 80w80 e
25 N f cff wiat Liv hpc 60w60 sk
a N f cff wat Liv hpa 60w60 ek
26 N1f cff wat Liv hpc 79w80 ae
a N f cff wat Liv hpa 79w80 as
27 N * cff wat Liv hpa 60w60 ek
a M * cff wat Liv hpc 60w60 ek
28 N m cff wat Liv hpc 80w80 5





67.7mg * P<.002 +
74.3mg * P<.009 +
39.0mg * P<.0005+









BENZO(a)PYRENE*** lOOng ..:. lug. 1 :10 : .100.. 1 :. 1g :10 : .100.1:0 1 :10
29 R b sda sat mix mix 30.30 r . .956mg P<.04 +
a R b sda sat for pam 30.30 r .972mg P<.03 +
BENZOIN
30 N f b6c *at TBA NXB 24m24
a N f b6c sat Liv NXB 24m24
b N f b6c sat Lun NXB 24m24
31 N m b6c sat TBA NXB 24m24
a N m b6c sat Liv NXB 24.24
b N m b6c sat Lun NXB 24m24
32 R f f34 sat TBA NXB 24m24
a R f f34 sat Liv NXB 24m24
33 R m f34 sat Liv NXA 24m24
a R m f34 sat TBA NXB 24m24
b R m f34 sat Liv NXB 24.24
2-BIPHENYLANINE .HCL
34 N f b6c sat --- NXA 24.24
a f b6c oat --- ang 24m24
b N f b6c sat TBA NXB 24m24
c N f b6c sat Liv NXB 24m24
d N f b6c sat Lun MXB 24.24
35 N m b6c sat ... XA 24m24
a N m b6c *at --- XA 24m24 5
b N m b6c sat TBA NXB 24m24 s
c N m b6c sat Liv NXB 24.24 e
d N m b6c *at Lun NXB 24.24 e
36 R f f34 sat TBA NXB 24.24
a R f f34 sat Liv NXB 24m24
37 R m f34 sat TBA MXB 24m24
a R m f34 sat Liv NXB 24m24
lOOng . . .:ug.:10. :100. g :.lg :10. :100.. : g :10
:> 6.83gm * P<.9 -
8.42gm * P<.4
no dre P-1.
:> 2.46gm * P<.6 -
3.56gm * P<.5
2.909m * P<.3
:> no dre P-I.
no dre P-1.
A e #88.2mg * P<.03 -
no dre P-1.
88.2mg * P<.03
lOOng .. : lug.:10. :100. 1g :. . :10. :100.. :19 :10
+ 1.12gm * P<.0005c




1.25gm * P<.02 a




:> no dre P-1. -
363.mg \ P<.2
:> no dre P-1. -
no dre P-1.
BIS(2-CHLORO-1-NETHYLETHYL) ETHER*** ..: ..lug..:10. :100. 1g : . . :10. :100..:. :10
38 N f b6c gav lun NXA 24.25 : + 311.mg * P<.002 c
a N f b6c gav lun a/a 24m25 381.mg * P<.006 c
b N f b6c gav sto NXA 24m25 +historicaL * P<.05 a
c N f b6c giv TBA MXB 24m25 231.mg * P<.2
d N f b6c gav Liv NXB 24.25 no dro P-1.
* N f b6c gav Lun NXB 24.25 311.mg * P<.002
39 N m b6c giv Liv NXA 24m24 + 138.mg * P<.002 c
a N m b6c gav liv hpc 24.24 229.mg * P<.004 c
b N m b6c gav Lun NXA 24.24 259.mg * P<.02 c
c N m b6c gav Lun a/a 24.24 306.mg * P<.03 c
d N m b6c gav TBA NXB 24.24 116.mg * P<.02SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
a c50613 606.mg 4.27gm 1/50
b c50613 666.mg 9.39g. 1/50
c c50613 1.36gm 12.8g. 0/50
d c50613 1.26gm n.s.s. 0/50
* c50613 304.mg n.s.s. 31/50

























19 1329 10.8mg n.s.s. 0/15
a 1329 10.8mg n.s.s. 0/15
b 1329 11.9mg n.s.s. 1/15
c 1329 1.65mg n.s.s. 0/15
20 1329 11.9sg n.s.s. 1/15
a 1329 1.65mg n.s.s. 0/15
BENZIDINE.2HCL 531-85-1
21 1577o 12.3mg 27.5mg 0/45
a 1577o 17.6mg 80.9mg
22 1577r 7.42mg 12.6mg
a 1577r 40.5mg 338.mg
23 1577o 35.9mg 414.mg
a 1577o 38.4mg 3.64gm
24 1577r 25.6mg 63.8mg
a 1577r 65.4mg n.s.s.
25 1577m 11.8mg 26.0mg
a 1577m 16.4mg 39.3mg
26 1577n 6.90mg 11.9mg
a 1577n 29.4mg 78.7mg
27 1577m 33.9mg 153.mg
a 1577m 46.4mg 353.mg
28 1577n 22.7mg 53.2mg


























































































































































29 1326 .376mg n.s.s. 3/64




30 c50011 572.mg n.s.s. 27/50 322.mg 35/50 644.mg
a c50011 1.93gm n.s.s. 2/50 322.mg 3/50 644.mg
b c50011 2.85gm n.s.s. 6/50 322.mg 5/50 644.mg
31 c50011 451.mg n.s.s. 31/50 297.mg 27/50 594.mg
a c50011 716.mg n.s.s. 16/50 297.mg 12/50 594.mg
b c50011 846.mg n.s.s. 5/50 297.mg 10/50 594.mg
32 c50011 22.3mg n.s.s. 42/50 12.5mg 41/50 25.0mg
a c50011 n.s.s. n.s.s. 0/50 12.5mg 0/50 25.0mg
33 c50011 30.5mg n.s.s. 0/50 5.00mg 0/50 10.0mg
a c50011 10.3mg n.s.s. 36/50 5.00mg 32/50 10.0mg





















34 c50282 527.mg 3.069m 0/50
a c50282 579.mg 4.87gm 0/50
b c50282 269.mg n.s.s. 31/50
c c50282 475.mg n.s.s. 7/50
d c50282 1.15gm n.s.s. 6/50
35 c50282 530.mg n.s.s. 0/50
a c50282 670.mg n.s.s. 0/50
b c50282 181.mg n.s.s. 37/50
c c50282 333.mg n.s.s. 14/50
d c50282 388.mg n.s.s. 16/50
36 c50282 122.mg n.s.s. 46/50
a c50282 115.mg n.s.s. 1/50
37 c50282 142.mg n.s.s. 43/50





























- - - :ang,h.m.
l iv:hpa,nnd,hpc.
lun:a/c,a/a.
- - - :ang,hes,h.m.






38 c50044 155.mg 1.459m 1/50 67.5mg 4/50 139.mg
a c50044 177.mg 4.889m 1/50 67.5mg 4/50 139.mg
b c50044 498.mg n.s.s. 0/50 67.5mg 0/50 139.mg
c c50044 75.0mg n.s.s. 26/50 67.5mg 29/50 139.mg
d c50044 269.mg n.s.s. 7/50 67.5mg 7/50 139.mg
* c50044 155.mg 1.45gm 1/50 67.5mg 4/50 139.mg
39 c50044 73.4mg 693.mg 13/50 68.8mg 23/50 140.mg
a c50044 117.mg 1.61gm 6/50 68.8mg 13/50 140.mg
b c50044 121.mg n.s.s. 6/50 68.8mg 15/50 140.mg
c c50044 138.mg n.s.s. 5/50 68.8mg 13/50 140.mg




































2/21168 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
* N m b6c gav liv NXB 24.24
f N U b6c gav lun NXB 24.24
BISPHENOL A
40 N f b6c *at TBA NXB 24.25
a N f b6c eat liv NXB 24.25
b N f b6c eat Lun NXB 24.25
41 N m b6c eat --- NXA 24.25
a N m b6c oat -- ym 24.25
b N m b6c eat pit crc 24.25
c N m b6c eat TBA NXB 24.25
d N m b6c eat Liv NXB 24.25
* N m b6c eat Lun NXB 24.25
42 R f f34 eat TBA NXB 24.25
a R f f34 set liv NXB 24.25
43 R m f34 oat *gL fba 24.25
a t m f34 eat TBA NXB 24.25
b R m f34 eat liv NXB 24.25
BUTYL BENZYL PHTHALATE*
44 N f b6c eat TBA NXB 24.24
a N f b6c oat Liv NXB 24.24
b N f b6c eat Lun NXB 24.24
45 N m b6c oat TBA NXB 24.24
a N m b6c eat Liv NXB 24.24
b N m b6c eat lun NXB 24.24
46 R f f34 eat ... NXA 24.24
a R f f34 eat... lu 24m24
b R f f34 eat TBA NXB 24.24
c R f f34 eat Liv NXB 24.24
47 R m f34 oat TBA MXB 29w29 s





bO0ng .. : lug.:10. :100. g :..g :10. :100. :1.g :10
:> no dre Pl. 1
5.31gm * P<.06
18.79g * P<.6






:> no dre Pl. 1
595.mg P<.6
A * t#675.mg P<.03 -
no dre P-1.
no dro P.1.
!OOng .. : lug.:10. :100. g :. 1g :10. :100.. : g. :10
:> no dre P-1.
8.39gm * P<.2
no dre P-1.
:> no dre P-I.
20.79m P<.8
no dre P-1.






BUTYLATED HYDROXYANISOLE lOOng.. : .lug. 1 :10 :..100.. : g. 1. :10 :..100..1:0 . :10
48 N b swi eat lun tur 24.24 r .> 5.119g P<.2
a N b swi eat liv tum 24.24 r no dre P-1.
BUTYLATED HYDROXYTOLUENE***
49 N f b6c eat Liv hnd 22m24 a
a N f b6c eat liv hpc 22m24 a
b N f b6c eat lun adc 22m24 a
c N f b6c eat lun ad. 22m24 a
50 N m b6c oat liv hnd 22m24 a
a N m b6c eat Lun ad. 22m24 a
b N m b6c eat Liv hpc 22m24 e
c N m b6c eat Liv has 22m24 a
d N m b6c eat Lun adc 22m24 a
51 N b swi aat Lun tum 24m24 r
a N b swi aat Liv tum 24m24 r
CAFFEINE***
52 R f ada gav mix mix 24m24 r
53 R m ada gav mix mix 24m24 r
a R m ada gav *so ben 24m24 r
b R m ada gav for pam 24m24 r
54 R f wis wat tba six 16824 a
55 R m wis wat tba mix 18m24 a
CAPROLACTAN
56 N f b6c aat TBA NXB 24m24
a N f b6c aat Liv NXB 24m24
b N f b6c sat Lun MXB 24m24
57 N m b6c aat TBA NXB 24m24
a N m b6c aat Liv MXB 24.24
b N m b6c aat Lun NXB 24m24
58 R f f34 oat TBA MXB 24m24
a R f f34 aat Liv MXB 24m24
59 R m f34 aat pit can 24m24
a R m f34 eat TBA MXB 24m24
b R m f34 aat Liv MXB 24m24
CARBAZOLE
60 N f b6c aat Liv hpc 22m24 a
a N f b6c eat for pam 22m24 a
b N f b6c aat for mix 22m24 a
c N f b6c aat Lun mix 22m24 a
61 N . b6c aat Liv hpc 22m24 a
a N m b6c eat for mix 22m24 a
b N m b6c eat for sqc 22m24 a
bO0ng . . .lug.:10. :100. g :. 1g :10. :100.:Ig. :10
























bO0ng .. : lug.:10. :100. g :..g :10. :100.. : g. :10
:> no dra P-1.
no dre P.1.
no dre Pal.
:> no dre P-1.
34.3gm * P<.8
no dro Pal.
:> no dre Pl. 1
no dre Pul.
A #3.569m * P<.05 -
no dra P-1.
5.69gm * P<.7
100ng ..:.1ug.:10. :100. 1g :. . :10. :100..:19 :10
+ . 102.mg Z P<.0005+
1.29gm Z P<.002 +
1.969m * P<.009 +
no dra P-1.
+ . 424.mg * P<.0005+
2.799m * P<.0005+
4.94gm * P<.002 +SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lIne 2Dose 2Inc Citation or Pathology
c50044 73.4mg 693.mg 13/50 68.8mg 23/50 140.mg 27/50
f c50044 121.mg n.s.s. 6/50 68.8mg 15/50 140.mg 13/50
BISPHENOL A (4,4'-isopropyLidenediphenoL) 80-05-7
40 c50635 1.089m n.s.s. 21/50 125.mg 17/50 626.mg
a c50635 1.83gm n.s.s. 0/50 125.mg 1/50 626.mg
b c50635 2.67gm n.s.s. 1/50 125.mg 1/50 626.mg
41 c50635 179.mg n.s.s. 2/50 116.mg 9/50 (578.mg
a c50635 192.mg n.s.s. 2/50 116.ig 8/50 (578.mg
b c50635 2.029m n.s.s. 0/50 116.mg 0/50 578.mg
c c50635 701.mg n.s.s. 23/50 116.mg 28/50 578.mg
d c50635 1.61gm n.s.s. 16/50 116.mg 14/50 578.mg
c50635 2.31gm n.s.a. 7/50 116.mg 2/50 578.mg
42 c50635 115.mg n.s.s. 47/50 47.7mg 45/50 95.4mg
a c50635 103.mg n.s.s. 4/50 47.7mg 6/50 (95.4mg
43 c50635 231.mg n.s.s. 0/50 38.1mg 0/50 76.3mg
a c50635 54.1mg n.s.s. 39/50 38.1mg 43/50 76.3mg




























BUTYL BENZYL PHTHALATE* 85-68-7
44 c54375 1.649m n.s.s. 33/50
a c54375 2.909m n.s.s. 2/50
b c54375 3.57gm n.s.s. 8/50
45 c54375 2.39gm n.s.s. 38/50
a c54375 2.499m n.s.s. 13/50
b c54375 5.49gm n.s.s. 17/50
46 c54375 639.mg n.s.s. 7/49
a c54375 673.mg n.s.s. 7/49
b c54375 402.mg n.s.s. 44/49
c c54375 1.65gm n.s.s. 1/49
47 c54375 n.s.s. n.s.s. 0/50













BUTYLATED HYDROXYANISOLE (BHA) 25013-16-5
48 1525 1.309m n.s.a. 1/47 625.mg























49 1528 1.409m n.s.s. 2/47
a 1528 2.269m n.s.s. 2/47
b 1528 2.899m n.s.s. 3/47
c 1528 3.819m n.s.s. 7/47
50 1528 784.mg n.s.s. 14/48
a 1528 1.489m n.s.s. 8/48
b 1528 1.53gm n.s.s. 11/48
c 1528 3.529m n.s.s. 4/48
d 1528 4.36gm n.s.s. 3/48
51 1525 640.mg 7.00gm 1/47
a 1525 3.029m n.s.s. 7/47
CAFFEINE*** 58-08-2
52 1326 471.mg n.s.s. 0/32
53 1326 113.mg n.s.s. 3/32
a 1326 163.mg n.s.s. 1/32
b 1326 177.ig n.s.s. 2/32
54 1526 76.3mg n.s.s. 41/50



















3/47 120.mg 5/46 600.mg
2/47 120.mg 1/46 600.mg
0/47 120.mg 1/46 600.mg
3/47 120.mg 2/46 600.mg
10/48 111.mg 13/50 554.mg
8/48 111.mg 9/50 554.mg
13/48 111.mg 12/50 554.mg
5/48 111.mg 2/50 554.ig





















56 c50646 1.629m n.s.s.
a c50646 13.49m n.s.s.
b c50646 26.99m n.s.s.
57 c50646 3.519m n.s.s.
a c50646 3.829m n.s.s.
b c50646 6.479m n.s.s.
58 c50646 361.mg n.s.s.
a c50646 n.s.s. n.s.s.
59 c50646 1.089m n.s.s.
a c50646 359.mg n.s.s.









































60 1481 64.8mg 174.mg 2/45
a 1481 663.mg 4.65gm 0/45
b 1481 1.15gm 83.3gm 0/45
c 1481 7.93gm n.s.s. 2/45
61 1481 281.mg 763.mg 9/46
a 1481 1.44gm 6.58gm 0/46








35/49 (360.09 24/43 749.mg 30/46)
5/49 360.mg 7/43 (749.mg 4/46)
5/49 360.mg 8/43 749.mg 6/46
0/49 360.mg 0/43 749.mg 1/46
12/42 332.mg 20/42 665.mg 37/48
0/42 332.mg 1/42 665.mg 11/48
0/42 332.mg 0/42 665.mg 7/48
Tsuda; jnci ,69,1383-1387;1982
169170 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
c N m b6c eat for pam 22.24 a
d N m b6c eat lun mix 22.24 a
TD50 2Tailpvl
DR AuOp
7.039m * P<.O1 +
no dre P-1.
CARRAGEENAN, ACID-DEGRADED*** O0ng. . u .. :l ug. 10 100. g :. 1 : 10 :..100.. : 1 : 10
62 R m f34 mat ctr mix 26w78 r . + . 2.439m P<.0005+
a R m f34 mat ctr sqc 26w78 r 3.33gm P<.003
63 R m f34 mat cLr mix 39w78 r . + . 1.499m P<.0005+
CHLORDANE*** bOng..: . .lug. 1 :10 :..100.. : g.1g :10 : .100.1:0 1 :10
64 N m can mat Liv tum 52w52 kr noTDS0 P<.3
CINNANYL ANTHRANILATE
65 N f b6c mat liv NXA 24m24
a N f b6c mat Liv hpc 24m24
b N f b6c mat TBA MXB 24m24
c N f b6c mat Liv NXB 24m24
d N f b6c mat Lun MXB 24m24
66 N m b6c mat Liv NXA 24m24
a N m b6c mat TBA NXB 24m24
b N m b6c mat Liv NXB 24m24
c N m b6c mat Lun MXB 24m24
67 R f f34 mat ut, map 24m24
a R f f34 mat TBA NXB 24m24
b R f f34 mat Liv NXB 24m24
68 R m f34 mat NXB MXB 24m24
a R m f34 mat NXA NXA 24m24
b R m f34 mat k/c NXA 24m24
c R m f34 mat pan NXA 24m24
d R m f34 mat TBA NXB 24m24
a R a f34 mat Liv NXB 24m24
CYTENBENA
69 N f b6c mat --- Lhc 24m24
a N f b6c mat Liv hpa 24m24
b N f b6c mat TBA NXB 24m24
c N f b6c mat Liv NXB 24m24
d N f b6c mat Lun NXB 24m24
70 N a b6c mat TBA NXB 24m24
a N m b6c mat Liv NXB 24m24
b N a b6c mat Lun NXB 24m24
71 R f f34 mat mgL fba 24m24
a R f f34 mat Liv nnd 24m24
b R f f34 mat TBA MXB 24m24
c R f f34 mat Liv NXB 24m24
72 R m f34 mat NXB NXB 24m24
a R m f34 mat muL mam 24m24
b R m f34 mat tnv men 24m24
c R m f34 mat TBA NXB 24m24
d R m f34 mat Liv MXB 24m24
DEXTRAN SULFATE SODIUN (DS-N-1)
73 R b aci mat itn mix 94w94 a
a R b aci mat cLr pam 94w94 m
b R b aci mat cLr sqc 94w94 m
1,2-DIALLYLHYDRAZINE.2HCL
74 N f swa wat Lun mix 83w83 ms
a N f swa wat Lun ado 83w83 es
b N f awa wat Lun adc 83w83 ms
c N f swa wat Liv hpt 83w83 *m
d N f swa wat Liv ang 83w83 ms
m N f swa wat Liv ago 8383 ms
75 N swaiwat lun mix 82w82 ms
a N m swa wat lun ada 82w82 ms
b N m swa wat Lun adc 82w82 ms
c N m swa wat Liv mix 82w82 ms
d N m awa mat Liv agm 82w82 es
4,4' -DIAblINOAZOBENZENE
76 N f bLd mat Lun mix 14m31 m
a N f bLd mat Liv mix 14m31 m
77 N m bLd eat Lun mix 14m31 a
a N m bLd mat Liv mix 14m31 a
4,41'-DIAMINOBENZANILIDE
78 N f bLd mat Lun mix 14m31 a
a N f bLd mat Liv mix 14m31 a
79 N m bLd mat Lun mix 14m31 a
a N m bLd eat Liv mix 14m31 a










+ :#1.469m \ P<.002 -
no dro P-1.
no dre P-1.
+ 7.00gm * P<.003
10.9gm * P<.03
12.19m * P<.03 c
17.5gm * P<.05 c
7.69gm * P<.7
9.409m * P<.3
lOOng .. : ..lug. : 10. : 100 mg. : :10 . :100 Ig. :10
























































no dre P-1.SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
c 1481 2.67gm 430.9m 0/46 166.mg 0/42 332.mg 1/42 665.mg 4/48
d 1481 4.29gm n.s.s. 4/46 166.mg 0/42 332.mg 1/42 665.mg 3/48
CARRAGEENAN, ACID-DEGRADED***
62 1517. 1.109m 7.809m 0/46 1.339m 8/42
a 1517. 1.369m 17.59m 0/46 1.339m 6/42
63 1517n 836.mg 3.009m 0/46 2.00gm 17/42
CHLORDANE*** 57-74-9






























































































CYTEMBENA (NCI uses CAS# 21739-91-3) 16170-75-5
69 c50737 21.8mg n.s.s. 0/50 5.12mg 3/50 10.2mg
a c50737 29.4mg n.s.s. 0/50 5.12mg 0/50 10.2mg
b c50737 7.91mg n.s.s. 26/50 5.12mg 23/50 10.2mg
c c50737 21.6mg n.s.s. 3/50 5.12mg 3/50 10.2mg
d c50737 50.0mg n.s.s. 7/50 5.12mg 4/50 10.2mg
70 c50737 4.29mg n.s.s. 28/50 5.12mg 30/50 10.2mg
a c50737 7.03mg n.s.s. 16/50 5.12mg 18/50 10.2mg
b c50737 12.7mg n.s.s. 6/50 5.12mg 7/50 10.2mg
71 c50737 2.45mg 18.3mg 13/50 2.99mg 22/50 5.97mg
a c50737 16.8mg n.s.s. 0/50 2.99mg 1/50 5.97mg
b c50737 2.63mg n.s.s. 38/50 2.99mg 44/50 5.97mg
c c50737 16.8mg n.s.s. 0/50 2.99mg 1/50 5.97mg
72 c50737 .624mg 1.90mg 3/50 2.99mg 37/50 (5.97mg
a c50737 1.15mg 4.05mg 3/50 2.99mg 26/50 (5.97mg
b c50737 1.14mg 6.60mg 0/50 2.99mg 11/50 (5.97mg
c c50737 .572mg 6.25mg 42/50 2.99mg 45/50 (5.97mg
d c50737 11.3mg n.s.s. 1/50 2.99mg 1/50 5.97mg
DEXTRAN SULFATE SODIUM (DS-M-1) (DS-N-1, NW=54,000) --
73 1482 110.mg 361.mg 0/20 450.mg 22/30
a 1482 181.mg 691.mg 0/20 450.mg 16/30
b 1482 607.mg n.s.s. 0/20 450.mg 4/30
1,2-DIALLYLHYDRAZINE.2HCI ---
74 1531 20.0mg 63.9mg 25/99
a 1531 28.4mg 93.7mg 20/99
b 1531 46.2mg 154.mg 6/99
c 1531 66.3mg n.s.s. 0/5
d 1531 389.mg n.s.s. 3/32
1531 328.mg n.s.s. 1/32
75 1531 20.2mg 65.8mg 26/100
a 1531 21.8mg 64.0mg 16/100
b 1531 35.3mg 122.mg 12/100
c 1531 290.mg n.s.s. 6/52




















































76 1368 75.0mg n.s.s. 11/40 5.91mg 7/40 17.7mg 11/40 35.5mg 14/39
a 1368 52.2mg n.s.s. 1/40 5.91mg 0/40 17.7mg 0/40 35.5mg 0/39
77 1368 70.9mg n.s.s. 10/39 5.45mg 6/39 16.4mg 10/40 32.7mg 14/40
a 1368 492.mg n.s.s. 1/39 5.45mg 0/39 16.4mg 1/40 32.7mg 0/40
4,4'-DIAMINOBENZANILIDE (DABA) 785-30-8
78 1368 77.8mg n.s.s. 11/40 5.91mg 13/40 17.7mg 10/38 35.5mg 15/40
a 1368 51.7mg n.s.s. 1/40 5.91mg 0/40 17.7mg 0/38 35.5mg 0/40
79 1368 90.6mg n.s.s. 10/39 5.45mg 17/39 16.4mg 10/40 32.7mg 13/39




Brkly Code172 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Not
2,6-DIAMINOTOLUENE.2HCL
80 N f b6c sat Liv hpc 24.24
a N f b6c sat TBA MXB 24.24
b M f b6c sat Liv MXB 24.24
c M f b6c sat Lun MXB 24.24
81 N m b6c sat --- Lym 24m24
a M m b6c oat TBA MXB 24.24
b N m b6c sat Liv MXB 24.24
c N m b6c sat Lun NXB 24.24
82 R f f34 eat TBA MXB 24.24
a R f f34 eat Liv MXB 24.24
83 R * f34 sat Liv NXA 24.24
a R m f34 sat pni isa 24m24
b R m f34 sat TBA MXB 24.24
c R m f34 sat Liv MXB 24.24
5,7-DIBROMOQUINOLINE
84 R f f34 sat liv hnd 24m24 a
85 R m f34 sat tes ict 24.24 a
a R m f34 sat Liv hnd 24,24 a
TD50 2Tailpvl
tes DR AuOp
lO0ng .:. .lug.. : 10. :100.. : l1g.. : 10. :100.. : Ig. :10








:> no dre P-1. -
455.mg * P<.1











3,5-DICHLORO(N-1,1-DINETHYL-2-PROPYNYL)BENZAMIDE .....10 .....::100.. :1mg. : 10... :100. :..g..:10
86 N m b6c aat Liv hnd 52w52 r . + . 43.4mg Z P<.002
a N m b6c sat Liv hpa 52w52 r 969.mg * P<.3
b M m b6c sat Liv hpc 52w52 r 56.6gm * P<1.
87 M m b6c sat Liv hnd 78w78 r . + . 286.mg * P<.003
a M m b6c eat Liv hpc 78w78 r 1.02gm * P<.06
b M m b6c sat Liv hpa 78w78 r 1.30gm * P<.2
88 M m b6c sat Liv hnd 24m24 r . + . 113.mg Z P<.002
a N m b6c sat Liv hpc 24m24 r 119.mg Z P<.0005+
b N m b6c eat Liv hpa 24m24 r 400.mg * P<.0005
2,6-DICHLORO-p-PHENYLENEDIAMINE
89 M f b6c sat liv MXA 24m26
a N f b6c sat Liv hpc 24m26
b M f b6c sat TBA MXB 24m26
c M f b6c sat Liv MXB 24m26
d M f b6c sat Lun MXB 24m26
90 M m b6c eat Liv MXA 24m26
a M m b6c sat Liv hpa 24m26
b M m b6c sat TBA MXB 24m26
c N m b6c sat Liv MXB 24m26
d N m b6c sat Lun MXB 24m26
91 R f f34 eat TBA MXB 24m26
a ft f134 eat Liv MXB 24m26
92 R m f34 sat TBA MXB 24m26
a R m f34 sat Liv MXB 24m26
DL -ETHIONINE***
93 R m fis sat Liv hpc 69w69 a
a R m fis sat Liv cLc 69w69 a
94 R m fi s at Liv hpc 52w52
95 R m fis sat Liv hpc 39w52
a R m fis sat Liv cLc 39w52
ETHYL ALCOHOL***
96 R ma da wat Liv hnd 30m30 a
a R masda wat pit tum 30m30 a
b R m sda wat adr tum 30m30 a
c R m sds wat pan tum 30m30 a
d R m ada wat Liv hpc 30m30 a
a R msda wat tba mix 30m30 a
ETHYL METHYLPHENYLGLYCIDATE
97 R f wis sat pit ads 24m24 a
a R f wis sat Liv hae 24m24 a
b R f wis sat tba ben 24m24 a
c R f wis eat tba maL 24m24 a
98 R m wis sat tea ict 24m24 a
a R m wis eat Liv tum 24m24 a
b R m wis sat tba ben 24m24 a
c R m wis sat tba maL 24m24 a
ETHYLENE OXIDE
99 R f sda gav sto mix 25m35 a
a R f sda gav for sqc 25m35 a
b R f sda gav mgL adf 25m35 s
lOOng .:. .:ug.. : 10. :100.. :1.mg.. : 10. :100.. :Ig. :10
+ 883.mg * P<.008 c




737.mg * P<.07 c




:> no dre P-I1.
2.96gm * P<.3
:> 914.mg * P<.9 -
340.mg * P<.05
























lOOng .. : lug.. : 10. :100.. : 1mg.. : 10. :100.. : Ig. :10
A 331.mg * P<.05 -
9.369m * P<.2 -
253.mg * P<.06 -
2.23gm * P<.2 -
1.15gm Z P<.2 -
no dre P-I1.
1.15gm * P<.5 -
4.11gm * P<.7 -
lOOng .. :. .ug.. : 10. :100.. : 1.mg.. : 10. :100.. :I1g. :10
7.43mg * P<.0005+
10.6mg * P<.0005+
10.0mg \ P<.02 -SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
2,6-DIAMINOTOLUENE.2HCL (2,6-toLuenediamine.2HCO 15481-70-6
80 c50317 54.8mg n.s.s. 0/50 6.40mg 0/50 12.9mg 3/50
a c50317 12.6mg n.s.s. 21/50 6.40mg 30/50 12.9mg 24/50
b c50317 32.0mg n.s.s. 4/50 6.40mg 3/50 12.9mg 7/50
c c50317 38.9mg n.s.s. 4/50 6.40mg 8/50 12.9mg 3/50
81 c50317 7.63mg n.s.s. 2/50 5.90mg 8/50 (11.9mg 2/50)
a c50317 12.2mg n.s.s. 31/50 5.90mg 36/50 11.9mg 26/50
b c50317 17.1mg n.s.s. 21/50 5.90mg 17/50 11.9mg 18/50
c c50317 25.7mg n.s.s. 11/50 5.90mg 13/50 11.9mg 7/50
82 c50317 22.7mg n.s.s. 42/50 12.4mg 38/50 24.8mg 39/50
a c50317 112.mg n.s.s. 0/50 12.4mg 0/50 24.8mg 2/50
83 c50317 47.6mg n.s.s. 0/50 9.90mg 2/50 19.8mg 4/50
a c50317 53.0mg n.s.s. 0/50 9.90mg 1/50 19.8mg 4/50
b c50317 16.3mg n.s.s. 32/50 9.90mg 38/50 19.8mg 36/50
c c50317 47.6mg n.s.s. 0/50 9.90mg 2/50 19.8mg 4/50
5,7-DIBROMOQUINOLINE 34522-69-5
84 1529 199.mg n.s.s. 3/44 50.0mg 2/37
85 1529 26.1mg n.s.s. 8/31 40.0mg 14/28














3,5-DICHLORO(N- 1,1 -DIMETHYL-2-PROPYNYL)BENZAMIDE 23950-58-5
86 1473m 19.5mg 263.mg 9/84 2.40mg 3/42 12.0mg 2/42 60.0mg 13/42 (300.mg 13/42) Essigmann;canr,41,2823-2831;1981
a 1473m 214.mg n.s.s. 2/84 2.40mg 1/42 12.0mg 2/42 60.0mg 3/42 300.mg 3/42
b 1473m 361.mg n.s.s. 2/84 2.40mg 0/42 12.0mg 2/42 60.0mg 2/42 300.mg 1/42
87 1473n 133.mg 1.86gm 13/84 2.40mg 14/42 12.0mg 9/42 60.0mg 13/42 300.mg 19/41
a 1473n 329.mg n.s.s. 3/84 2.40mg 3/42 12.0mg 3/42 60.0mg 4/42 300.mg 6/41
b 1473n 375.mg n.s.s. 3/84 2.40mg 4/42 12.0mg 4/42 60.0mg 2/42 300.mg 6/41
88 14730 56.1mg 544.mg 22/126 2.40mg 14/63 12.0mg 24/63 60.0mg 26/63 (300.mg 19/63)
a 1473o 64.5mg 323.mg 6/126 2.40mg 9/63 12.0Omg 12/63 60.0Omg 20/63 (300.mg 14/63)
b 1473o 247.mg 756.mg 5/126 2.40mg 6/63 12.0mg 7/63 60.0mg 8/63 300.mg 28/63
2,6-DICHLORO-p-PHENYLENEDIAMINE 609-20-1
89 c50260 409.mg 18.59m 6/50 121.mg 6/50 362.mg
a c50260 770.mg n.s.s. 2/50 121.mg 2/50 362.mg
b c50260 273.mg n.s.s. 31/50 121.mg 26/50 362.mg
c c50260 409.mg 18.5gm 6/50 121.mg 6/50 362.mg
d c50260 1.679m n.s.s. 2/50 121.mg 2/50 362.mg
90 c50260 284.mg n.s.s. 16/50 111.mg 19/50 334.mg
a c50260 431.mg n.s.s. 4/50 111.mg 7/50 334.mg
b c50260 299.mg n.s.s. 32/50 111.mg 30/50 334.mg
c c50260 284.mg n.s.s. 16/50 111.mg 19/50 334.mg
d c50260 559.mg n.s.s. 13/50 111.mg 5/50 (334.mg
91 c50260 66.1mg n.s.s. 49/50 92.8mg 45/50 (278.mg
a c50260 757.mg n.s.s. 3/50 92.8mg 2/50 278.mg
92 c50260 58.3mg n.s.s. 42/50 37.1mg 37/50 74.2mg
a c50260 132.mg n.s.s. 1/50 37.1mg 3/50 74.2mg
DL*ETHIONINE*** 67-21-0
93 1491m 2.49mg 11.5mg
a 1491m 38.3mg n.s.s.
94 1491n 6.33mg 27.2mg
95 1491o n.s.s. 6.85mg
a 1491o 40.8mg n.s.s.
ETHYL ALCOHOL*** 64-17-5
96 1440 4.47gm 29.0gm
a 1440 4.89gm 32.1gm
b 1440 7.38gm 29.9gm
c 1440 7.38gm 29.9gm







































97 1383 126.mg n.s.s. 18/43 10.0mg 30/44 50.0mg 24/41 250.mg 31/43
a 1383 1.529m n.s.s. 0/44 10.0mg 0/44 50.0mg 0/42 250.mg 1/45
b 1383 92.7mg n.s.s. 24/44 10.0mg 35/44 50.0mg 33/42 250.mg 37/45
c 1383 601.mg n.s.s. 1/44 10.0mg 3/44 50.0mg 3/42 250.mg 5/45
98 1383 335.mg n.s.s. 2/38 8.00mg 8/35 40.0mg 1/35 200.mg 8/36
a 1383 50.8mg n.s.s. 0/37 8.00mg 0/38 40.0mg 0/39 200.mg 0/39
b 1383 230.mg n.s.s. 10/38 8.00mg 20/39 40.0mg 11/39 200.mg 17/39
c 1383 491.mg n.s.s. 2/38 8.00mg 6/39 40.0mg 4/39 200.mg 5/39
ETHYLENE OXIDE 75-21-8
99 1486 5.12mg 11.3mg 0/50 1.53mg 12/50 6.11mg 35/50
a 1486 7.06mg 16.9mg 0/50 1.53mg 8/50 6.11mg 29/50













173174 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Nc
DI(2-ETHYLHEXYL)ADIPATE
100 N f b6c mat Liv hpc 24.24
a N f b6c sat Liv MXA 24.24
b N f b6c mat TBA MXB 24.24
c N f b6c eat Liv MXB 24,24
d N f b6c eat Lun MXB 24m24
101 N m b6c eat Liv MXA 24.24
a N m b6c mat Liv hpa 24.24
b N m b6c mat TBA MXB 24.24
c N m b6c mat Liv MXB 24.24
d N m b6c eat Lun NXB 24.24
102 R f f34 mat TBA MXB 24.24
a R f f34 mat Liv MXB 24.24
103 R m f34 oat TBA NXB 24.24
a R m f34 mat Liv MXB 24.24
DI(2-ETHYLHEXYL)PHTHALATE
104 N f b6c eat Liv NXA 24.24
a N f b6c eat Liv hpc 24.24
b N f b6c sat TBA MXB 24.24
c M f b6c eat Liv NXB 24.24
d N f b6c .at Lun NXB 24.24
105 N m b6c eat Liv MXA 24.24
a N m b6c sat Liv hpc 24.24
b N m b6c mat TBA NXB 24.24
c N m b6c eat Liv MXB 24.24
d N m b6c mat Lun MXB 24.24
106 R f f34 sat Liv MXA 24.24
a R f f34 sat Liv hpc 24a24
b R f f34 eat Liv nnd 24a24
c R f f34 mat TBA MXB 24a24
d R f f34 sat Liv MXB 24m24
107 R m f34 mat Liv MXA 24m24
a R m f34 mat liv hpc 24.24
b R m f34 mat TBA MXB 24.24
c R m f34 mat Liv MXB 24m24
FLUOMETURON
108 M f b6c mat TBA MXB 24m24
a N f b6c mat Liv MXB 24,24
b N f b6c mat Lun MXB 24.24
109 N m b6c mat liv NXA 24.24
a M m b6c aat TBA MXB 24.24
b N m b6c aat Liv MXB 24.24
c N m b6c mat Lun MXB 24.24
110 R f f34 mat TBA MXB 24.24 v
a R f f34 mat Liv MXB 24.24 v
111 R m f34 mat Liv nnd 24.24 v
a R . f34 mat TBA MXB 24.24 v
b R m f34 sat Liv MXB 24,24 v
TD50 2Tailpvl
DR AuOp otes
bO0ng .. : lug.:10. :100. g : ..g :10. :100.. : . :10





* 5.339 * P<.06 c




:> no dre P-I. -
14.59g * P<.6
:> no dro P-1. -
no dre P-1.
lOOng .. : ..ug.:10. :100. 1g : . 1g : 0. :100.. : g :10





* 4.05gm * P<.03 c




+ : 2.28g. * P<.0005c




A 2.41gm * P<.03 c
6.85gm * P<.1 c
*no dre P-1.
2.41gm * P<.03
00ng .. : ..ug.:10. :100. g :. 1g :10. :100.. : g :10
:> 369.mg * P<.2 -
1.23gm * P<.4
no dre P-1.




:> no dre P-1. -
no dre P-1.
A * #55.4mg * P<.04 -
no dre P-1.
55.4mg * P<.04
FORMALDEHYDE lOOng.. : . .. 1ug .1.0 :1 00 1.g. 1:0.100.1:0 1 :10
112 H m syg inh res tu. 94w94 r .> no dre P-1.
113 H m syg inh res tum 25.25 rs .> no dre PI..
GENFIBROZIL
114 N f cdl *at tba mix 78w78 a
a N f cdl mat tba ben 78w78 a
b N f cdl mat tba mal 78w78 a
115 N m cdl mat tba mix 78w78 a
a N m cdl mat tba ban 78w78 o
b N m cdl mat tba maL 78w78 a
116 R f cdr mat tba mix 24m24 a
a R f cdr mat tba ben 24m24 a
b R f cdr eat tba maL 24m24 a
117 R m cdr mat tba mix 24m24 a
a R m cdr eat tba ben 24m24 a
b R m cdr mat tba mal 24m24 a













beta-N- gamma-L(+).GLUTANYLJ -4-HYDROXYMETHYLPHENYLHYDRAZINE..:..100...... ............. ......19 ..... :1mg . 10 .100.1g . 10
118 N f swa wat liv ang 28.28 a .> 2.729m
a N f swa wat Lun ade 28m28 e 3.299m
b N f awa wat lun mix 28.28 . no dre
119 N m swa wat liv ang 28m28 aes .> 2.049m
a N m swa wat liv hpt 28m28 ams 3.319m
b N m swa wat lun ada 28,28 ams no dre







P-1. _SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
DI(2-ETHYLHEXYL)ADIPATE 103-23-1
100 c54386 1.579m 9.40gm
a c54386 2.29gm 11.3g.
b c54386 3.44gm n.s.s.
c c54386 2.29gm 11.3gm
d c54386 17.8gm n.s.s.
101 c54386 2.25gm n.s.s.
a c54386 3.629m n.s.s.
b c54386 2.99gm n.s.s.
c c54386 2.25gm n.s.s.
d c54386 2.049m n.s.s.
102 c54386 699.mg n.s.s.
a c54386 4.76gm n.s.s.
103 c54386 1.47gm n.s.s.






















































104 c52733 2.119m 6.929m
a c52733 2.62gm 7.769m
b c52733 695.mg 8.22gm
c c52733 2.11gm 6.92gm
d c52733 9.03gm n.s.s.
105 c52733 1.81gm n.s.s.
a c52733 3.02gm n.s.s.
b c52733 1.71gm n.s.s.
c c52733 1.81gm n.s.s.
d c52733 8.12gm n.s.s.
106 c52733 1.339m 4.98gm
a c52733 2.30gm 12.1gm
b c52733 2.28gm n.s.s.
c c52733 666.mg n.s.s.
d c52733 1.33gm 4.98gm
107 c52733 1.08gm n.s.s.
a c52733 2.30gm n.s.s.
b c52733 940.mg n.s.s.
c c52733 1.08gm n.s.s.
FLUOMETURON 2164-17-2
108 c08695 127.mg n.s.s.
a c08695 324.mg n.s.s.
b c08695 636.mg n.s.s.
109 c08695 103.mg n.s.s.
a c08695 80.2mg n.s.s.
b c08695 103.mg n.s.s.
c c08695 262.mg n.s.s.
110 c08695 16.0mg n.s.s.
a c08695 77.6mg n.s.s.
111 c08695 21.1mg n.s.s.
a c08695 9.84mg n.s.s.
b c08695 21.1mg n.s.s.
FORMALDEHYDE 50-00-0
112 1414m 6.50mg n.s.s.
113 1414n 25.6mg n.s.s.
117-81-7
1/50 1.52gm 12/50 3.19gm 18/50
0/50 1.52gm 7/50 3.19gm 17/50
20/50 1.52gm 35/50 (3.19gm 35/50)
1/50 1.52gm 12/50 3.19gm 18/50
0/50 1.529m 1/50 3.19gm 2/50
14/50 1.41gm 25/49 2.96gm 29/50
9/50 1.41gm 14/49 2.96gm 19/50
29/50 1.41gm 37/49 2.969m 38/50
14/50 1.41gm 25/49 2.96gm 29/50
10/50 1.41gm 9/49 2.96gm 7/50
0/50 591.mg 6/50 1.23gm 13/50
0/50 591.mg 2/50 1.23gm 8/50
0/50 591.mg 4/50 1.23gm 5/50
41/50 591.mg 43/50 1.23gm 49/50
0/50 591.mg 6/50 1.23gm 13/50
3/50 466.mg 6/50 986.mg 12/50
1/50 466.mg 1/50 986.mg 5/50
36/50 466.mg 35/50 986.mg 34/50























































Dalboy;txcy,24,9- 14;1982 0/50 .772mg 0/50
0/132 1.29mg 0/88
GEMFIBROZIL 25812-30-0
114 1518n 40.2mg n.s.s.
a 1518n 44.7mg n.s.s.
b 1518n 83.1mg n.s.s.
115 1518n 28.5mg n.s.s.
a 1518n 48.8mg n.s.s.
b 1518n 62.9mg n.s.s.
116 1518m 11.2mg n.s.s.
a 1518m 15.0mg n.s.s.
b 1518m 35.3mg n.s.s.
117 1518m 2.62mg n.s.s.
a 1518m 3.21mg n.s.s.













3.90mg 23/72 39.0mg 25/72
3.90mg 15/72 39.0mg 19/72
3.90mg 10/72 39.0mg 10/72
3.60mg 46/72 36.0mg 45/72
3.60mg 37/72 36.0mg 33/72
3.60mg 20/72 36.0mg 16/72
1.50mg 50/50 15.0mg 44/50
1.50mg 50/50 15.0mg 41/50
1.50mg 8/50 15.0mg 11/50
1.20mg 44/50 12.0mg 47/50
1.20mg 39/50 12.0mg 45/50
1.20mg 18/50 12.0mg 22/50
FitzgeraLd;jnci,67,1105-1115;1981
beta-N-[ gamma-L(+)-GLUTAMYL -4-HYDROXYMETHYLPHENYLHYDRAZINE (agaritine) 2757-90-6
118 1584 500.mg n.s.s. 1/56 125.mg 2/34
a 1584 362.mg n.s.s. 20/94 125.mg 12/50
b 1584 458.mg n.s.s. 29/94 125.mg 13/50
119 1584 311.mg n.s.s. 3/83 104.mg 2/25
a 1584 396.mg n.s.s. 1/83 104.mg 1/25
b 1584 643.mg n.s.s. 13/100 104.mg 4/47
c 1584 567.mg n.s.s. 19/100 104.mg 6/47
Toth;acnr, 1,255-258;1981/1982a
175176 GOLD ETAL.
Spe Strain Site Xpo +Xpt TD50 2TailpvI
Sex Route Hist Notes DR AuOp
GUAR GUN bOOng..:. .lug... -10 ...:.100... .lug... -10 ....100... Ig19... -10
120 N f b6c mat TBA NXB 24.25 :no dre P-l. -
a N f b6c mat Liv NXB 24.25 no dre P-1.
b N f b6c eat Lun NXB 24.25 no dre P-1.
121 N m b6c eat TBA NXB 24.24 :no dre P-1. -
a N m b6c mat Liv NXB 24.24 no dre P-I.
b N m b6c mat Lun NXB 24.24 no dre P-1.
122 R f f34 eat TBA NXB 24.24 .> no dre P-I. -
a R f 134 eat Liv NXB 24.24 no dre P-1.
123 R m 134 mat sub fib 24.24 #13.4gm * P<.03 -
a R a 134 mat TBA NXB 24.24 16.5gm * P<.9
b R a 134 mat Liv NXB 24.24 no dre P-1.
GUN ARABIC lOOng. .:. .ug... .10 ...:.100. 1. :.mg... .10 ...:.100... .Ig ...:.10
124 N f b6c mat TBA NXB 24.24 :>no dre P-1. -
a N f b6c eat Liv NXB 24.24 31.1gm * P<.06
b N f b6c mat Lun NXB 24.24 24.7g.m P<.3
125 N m b6c eat he. 24.24 #80.8g. P<.05 -
a N m b6c mat TBA NXB 24.24 46.0gm IP<.8
b N mi b6c mat Liv NXB 24.24 no dre P-I.
c N m b6c mat Lun NXB 24.24 no dre P-I.
126 R f 134 mat TBA NXB 24.24 :> 8.31g. * P<.7 -
a R f 134 mat Liv NXB 24.24 no dre P-I.
127 R m 134 mat TBA NXB 24.24 :>7.97gm * P<.7 -
a R m 134 mat Liv NXB 24.24 33.5g. * P<.7
-HYDRAZINE SULFATE*** bOOng..:.. lug...:.10 ...:.100..lu:.g... .10 ....100...:.Ig ...:.10
128 N b swi gay Lun tum 54w54 r. + . 3.92mg P<.0005+
a N b swi gay Liv turn 54w54 r no dre P-I.
8-HYDROXYQUINOLINE*** lOOng. .. . lug...:.10 ....100. la :.g.....10 ...:.100.... g1 ...:.10
129 Rft 1 34 mat Liv hnd 24m24 m .> no dre P-1. -
130 ft. 134 mat Liv hnd 24.24. . 269.mg P<.04 -
ISONIAZID*** lOOng. .: .. lug...:.10 ....100.. 1 : mg...:.10 ...:.100... .Ig ...:.10
131 N b swi gay Lun tum 97w97 r~ + .24.5mg P<.0005+
a N b swi gay Liv tum 97w97 r no dre P-I.
LOCUST BEAN GUN
132 N f b6c mat pit adn 24m24
a N f b6c mat uta map 24m24
b N f b6c mat TBA NXB 24m24
c N f b6c eat Liv NXB 24m24
d N f b6c eat Lun NXB 24m24
133 N m b6c mat Lun a/a 24m24
a N m b6c mat TBA NXB 24m24
b N m b6c mat Liv NXB 24m24
c N m b6c mat Lun NXB 24.24
134 Rft 1 34 mat adr coin 24.24
a Rft 1 34 mat TBA NXB 24.24
b Rft 1 34 mat Liv NXB 24m24
135 ft m 134 mat TBA NXB 24m24
a ft m 134 mat Liv NXB 24m24
NALEIC HYDRtAZIDE***
136 N f cb6 gay Liv tum 28.28 a
a N fcb6 gav Lun tum 28a28m9
b N fcb6 gav tba tum 28m28mo
137 N m cb6 gay Lun tum 2M28 a
a N m cb6 gay Liv tum 28m28 a
b N m cb6 gay tba tum 28m28 a
NALONALDEHYDE, SODIUN
138 N f swi wat Liv hpt 52w52 a
a N f swi wat Liv mix 52w52 a
b N f swi wat Liv ham 52w52 a
c N f swi wat Liv hnd 52w52 a
d N f swi wat Lun ads 52w52 a
D-NANNITOL
139 N f b6c mat --- hes 24m24
a N f b6c mat --- LLm 24m24
b N f b6c mat TBA NXB 24,24
c N f b6c mat Liv NXB 24m24
d N f b6c mat Lun NXB 24m24
140 N m b6c mat TBA NXB 24m24
a N m b6c mat Liv NXB 24m24
b N m b6c mat Lun NXB 24m24
141 Rft 1 34 mat TBA NXB 24m24













:> no dre P-I. -
516.gm *Psl.
bOOng..: .. lug... .10...:.100.1. :.mg... .10...:.100... .Ig...:.10
.> ~~no drm P-1. -




no drm P-1. -
lOOng. .. . lug... .10 ....100.l.u:.Ig... .10 ....100... .Ig...:.10




no dre P-1. -






no drm Pal. -
no drm P-1.
98.1gm *P<.8
:> 5.00gm \P<.7 -SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
GUAR GUM 9000-30.0
120 c50395 8.80gm n.s.s.
a c50395 27.4gm n.s.s.
b c50395 33.9gm n.s.s.
121 c50395 8.14gm n.s.s.
a c50395 7.71gm n.s.s.
b c50395 21.6gm n.s.s.
122 c50395 2.53gm n.s.s.
a c50395 18.5gm n.s.s.
123 c50395 5.10gm n.s.s.
a c50395 1.29gm n.s.s.













3.16gm 26/50 6.32gm 27/50
3.16gm 2/50 6.329m 4/50
3.16gm 1/50 6.32gm 3/50
2.92gm 33/50 5.89gm 32/50
2.929m 12/50 (5.899m 7/50)
2.929m 9/50 5.89gm 8/50
1.249m 47/50 2.489m 46/50
1.24gm 1/50 2.48gm 1/50
990.Mg 1/50 1.989m 4/50
990.mg 41/50 1.98gm 42/50









GUM ARABIC (gum acacia) 9000-01-5
124 c50748 6.45gm n.s.s. 30/50
a c50748 12.2gm n.s.s. 3/50
b c50748 6.59gm n.s.s. 3/50
125 c50748 24.59m n.s.s. 0/50
a c50748 5.01gm n.s.s. 36/50
b c50748 12.49m n.s.s. 16/50
c c50748 12.1gm n.s.s. 12/50
126 c50748 1.29gm n.s.s. 45/50
a c50748 10.2gm n.s.s. 3/50
127 c50748 1.08gm n.s.s. 40/50
a c50748 4.15gm n.s.s. 4/50
3.19gm 33/50 6.38gm 31/50
3.199m 2/50 6.38gm 10/50
3.19gm 7/50 (6.389m 1/50)
2.949m 0/50 5.899m 3/50
2.949m 28/50 5.899m 40/50
2.949m 11/50 5.89gm 15/50
2.94gm 10/50 5.899m 12/50
1.23gm 46/50 2.459m 47/50
1.239m 3/50 2.459m 2/50
981.mg 45/50 1.969m 42/50









128 1525 2.23mg 7.57mg 1/47
a 1525 28.4mg n.s.s. 7/47
8-HYDROXYQUINOLINE*** 148-24-3
129 1529 285.mg n.s.s. 3/44
130 1529 81.4mg n.s.s. 0/31
ISONIAZID*** (INN) 54.85.3
131 1525 13.0mg 55.8mg 1/47
a 1525 116.mg n.s.s. 7/47








LOCUST BEAN GUM (carob seed gum) 9000-40-2
132 c50419 6.98gm n.s.s. 0/50 3.19gm 4/50 (6.449m 1/50)
a c50419 26.29m n.s.s. 0/50 3.199m 0/50 6.44gm 3/50
b c50419 4.029m n.s.s. 45/50 3.199m 36/50 (6.449m 30/50)
c c50419 34.89m n.s.s. 3/50 3.19gm 2/50 6.44gm 2/50
d c50419 29.4gm n.s.s. 5/50 3.19gm 2/50 6.44gm 4/50
133 c50419 2.90gm n.s.s. 7/50 2.94gm 17/50 (5.94gm 11/50)
a c50419 5.06gm n.s.s. 36/50 2.949m 41/50 5.94gm 38/50
b c50419 14.0gm n.s.s. 18/50 2.94gm 16/50 5.94gm 14/50
c c50419 9.89gm n.s.s. 14/50 2.94gm 21/50 5.94gm 14/50
134 c50419 4.97gm n.s.s. 1/50 1.239m 4/50 2.459m 6/50
a c50419 1.74gm n.s.s. 44/50 1.23gm 43/50 2.45gm 42/50
b c50419 n.s.s. n.s.s. 0/50 1.23gm 0/50 2.45gm 0/50
135 c50419 1.789g n.s.s. 37/50 981.mg 35/50 1.96gm 35/50
a c50419 9.239m n.s.s. 1/50 981.mg 2/50 1.96gm 1/50
MALEIC HYDRAZIDE*** (1,2-dihydro-3,6-pyridazinedions) 123-33-1
136 1520 340.mg n.s.s. 1/12 72.9mg 2/35
a 1520 394.mg n.s.s. 2/12 72.9mg 2/35
b 1520 51.4mg n.s.s. 5/12 72.9mg 22/35
137 1520 395.mg n.s.s. 0/11 72.9mg 1/37
a 1520 237.mg n.s.s. 1/11 72.9mg 4/37
b 1520 112.mg n.s.s. 7/11 72.9mg 18/37
MALONALDEHYDE, SODIUM 24382-04-5
138 1521 1.14mg n.s.s. 0/97p 100.ug 0/49 1.00mg 2/50 (10.0mg 0/48)
a 1521 5.07mg n.s.s. 1/97p 100.ug 2/49 1.00mg 4/50 10.0mg 6/48
b 1521 7.78mg n.s.s. 1/97p 100.ug 1/49 1.00mg 0/50 10.0mg 4/48
c 1521 10.3mg n.s.s. 0/97p 100.ug 1/49 1.00mg 2/50 10.0mg 2/48
d 1521 14.3mg n.s.s. 6/97p 100.ug 4/49 1.00mg 5/50 10.0mg 2/48
D-MANNITOL 69-65-8
139 c50362 17.79m n.s.s. 0/50 3.19gm 2/50 6.38gm 3/50
a c50362 19.59m n.s.a. 0/50 3.19gm 2/50 6.38gm 4/50
b c50362 11.29m n.s.s. 26/50 3.19gm 24/50 6.38gm 18/50
c c50362 25.7gm n.s.s. 3/50 3.19gm 3/50 6.38gm 2/50
d c50362 36.9gm n.s.s. 3/50 3.199m 2/50 6.38gm 1/50
140 c50362 10.6gm n.s.s. 33/50 2.94gm 26/50 5.89gm 26/50
a c50362 14.5gm n.s.s. 14/50 2.94gm 14/50 5.89gm 11/50
b c50362 10.7gm n.s.s. 9/50 2.94gm 12/50 5.89gm 11/50


















177178 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
a ft f f34 oat Liv NXB 24.24
142 R m f34 oat TBA NXB 24.24




:> no dre P.I. -
18.0gm * P<.i
2-NETHOXY-4-ANINOAZOBENZENE lOOng..:. .Iug...:.10 ...:.100...:.lug.....10 ...:.100...:.Ig...:.10
143 N f b6c eat Liv tumn 56w56 r. no dre P-1. -
144 N m b6c oat Liv turn 56w56 r .> no dre. P.1. -
3-NETHOXY-4-ANINOAZOBENZENE lOOng. .. . lug...:.10 ....100...:.lug...:.10... ..100 ....Ig ...:.10
145 N f b6c oat Liv hpa 56w56 r . + . 60.2mg * Pc.005 +
146 N m b6c oat Liv turn 56w56 r .> no dre Pl.1 -
METHYL CLOFENAPATE lOOng. .: . .ug...:.10 ....100.. lu.g...:.10 ...:.100...I:g ...:.10
147 ft m f34 oat Liv hpc 75w75 or <+ noTD5O P<.0005+
N-NETHYL.N.FORNYLHYDRAZINE*** lOOng. .:. .ug...:.10 ...:.100...:.lug...:.10 ...:.100...:.Ig ....10
148 N f saw wet Lun mix 23.24 nos + ..745mg * P<.0005+
a N f iwa wit Lun adc 23.24 ases 1.12mg * P<.0005
b N f awa wit Lun ado 23.24 aes 1.50mg * P<.002
c N f swa wit Liv hpt 23.24 ass 9.23mg * P<.2 -
d N f awa wit Liv agm 23.24 aes 23.8mg * P<.5 -
149 N m awa wit Lun mix 23.24 isaes+ .865mg * P<.0005+
a N m swa wit Lun ado 23.24 ies 1.30mg * P<.002
b N m awe wit stg pLa 23.24 ass 3.43mg \P<.0l -
c N m swa wit Lun adc 23.24 isa 2.48mg *P<.03
d N m swa wit sub fbi 23.24 isa 2.60mg\ P<.02 -
o N m awe wit for sqp 23.24 iesa 11.2mg* P<.02 -
f N m awa wit Liv mix 23.24 isa no dro P-1.
NETHYL LINOLEATE HYDROPEROXIDE lOOng..:. .lug...:.10 ....100. 1. : mg...:.10 ...:.100... g1 ...:.10
150 ft m wis gay git mix 30w87 a .> no dre
a ftm wisn gay Liv tum 3NW7 a no dre
NETHYL LINOLEATE, NATIVE lOOng..:.. lug...:.10 ...:.100. 1. : mg...:.10... ..100... Igl ...:.10
151 ft m wis giv git mix 30w87 a .> no dre





N-NETHYL-N'.NITRtO.N.NITRtOSOGUANIDINE***..:..Iug...:.10 ...:.100. 1. : mg...:.10 ....100...I:g ...:.10
152 Rtm wis wit git mix 32w87 o . + . .581mg * P<.0005+
a ft m wis wit Liv turn 32w87 a no dre P-1.
3-NETHYLCHOLANTHRENE***
153 ft m Leo oat Liv turn 26w65
154 ft m Leo oat Liv turn 39w65
155 ft m Leo oat Liv turn 65w65
6-NETHYLQUINOLINE
156 ft f f34 oat Liv hnd 24.24 a
157 ft m f34 oat Liv hnd 24.24 a
8-NETHYLQUINOLINE
158 ft f f34 oat Liv hnd 24m24 o
159 ft m f34 oat Liv hnd 24.24 o
2.NAPHTHYLANINE***
160 ft f wis gay ubL mix 13m23 or
2-NAPHTHYLANINO,1-SULFONIC ACID
161 N f bLd oat Lun mix 15m33 a
a N f bLd oat Liv mix 15m33 o
162 N m bLd oat Lun mix 15.33 o
a N m btd oat Liv mnix 15m33 a
NICOTINE. HCL
163 N f awa wit
a Nfaswa wat
164 N m swa wit
a Nua wa wat
NICOTINIC ACID
165 N f swa wit
a N frswa wat
166 N mn swa wit
a Numawsawat
Lun turn 28.29 0
Liv mix 28.29 o
Liv mix 26.28 0
Lun turn 26.28 a
Lun turn 32.32 a
Liv mix 32rn2 o
Lun turn 28rn28 5
Liv mix 28m28 a
NITRATE, SODIUM***
167 ft f f34 oat Liv mix 24.29 a
a ft f f34 oat tba mix 24.29 a
168 ft m f34 oat Liv mix 24rn29 a
a ft m f34 sat tba mix 24m29 a












lOOng. .:. .lug ....10...:.100. 1. :mg...:.10....100...:.Ig ...:.10
.> ~~no dro P-1. -
.> ~~~no dro P-1.-
lOOng..:.. lug...:.10...:.100 .1.:mg.....10...:.100...:.Ig ...:.10
A ~~~~~61.6mng P<.02 +































2.62gm * P<.6SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
Citation or Pathology RefNum LoConf UpConf Cntrl lDose lIne 2Dose 2Inc
a c50362 n.s.s. n.s.s. 0/50 1.239m 1/50 2.45gm 0/50
142 c50362 1.779m n.s.s. 40/50 981..g 40/50 1.96g. 36/50
a c50362 6.18gm n.s.s. 0/50 981.mg 2/50 1.969m 2/50
2-METHOXY-4- AMINOAZOBENZENE *--
143 1500 90.9mg n.s.s. 0/13 117.mg 0/13
144 1500 83.9mg n.s.s. 0/13 108.mg 0/13
3-METHOXY-4-AMINOAZOBENZENE 3544-23-8
145 1500 25.8mg 388.mg 0/13 78.0mg 1/13 117.mg 6/13
146 1500 27.7mg n.s.s. 0/13 72.0mg 0/10 108..g 0/12
METHYL CLOFENAPATE 21340-68-1
147 1478 n.s.s. 9.17mg 0/10 40.0mg 14/14
N-METHYL-N-FORMYLHYDRAZINE*** 758-17-8
148 1266 .444mg 1.77mg 29/94 .500mg 31/48 1.00mg 32/48
a 1266 .665mg 2.72mg 14/94 .500mg 23/48 1.00mg 22/48
b 1266 .779mg 7.82mg 20/94 .500mg 23/48 1.00mg 21/48
c 1266 2.27mg n.s.s. 0/50 .500mg 2/23 1.00mg 0/17
d 1266 4.03mg n.s.s. 3/77 .500mg 1/45 1.00mg 3/38
149 1266 .488mg 2.69mg 19/83 .417mg 27/45 .833mg 24/47
a 1266 .686mg 5.95mg 13/83 .417mg 20/45 .833mg 18/47
b 1266 1.04mg 215.mg 0/80 .417mg 3/39 (.833mg 0/43)
c 1266 1.08mg n.s.s. 9/83 .417mg 14/45 .833mg 11/47
d 1266 .916mg n.s.s. 1/83 .417mg 5/45 (.833mg 0/47)
1266 3.38mg n.s.s. 0/80 .417mg 0/39 .833mg 3/43
f 1266 3.97mg n.s.s. 5/80 .417mg 3/39 .833mg 2/43
METHYL LINOLEATE HYDROPEROXIDE 27323-65-5
150 1475 41.6mg n.s.s. 0/30 9.61mg 0/30
a 1475 41.6mg n.s.s. 0/30 9.61mg 0/30
METHYL LINOLEATE, NATIVE - - -
151 1475 42.0mg n.s.s. 0/30 9.71mg 0/30
a 1475 42.0mg n.s.s. 0/30 9.71mg 0/30
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE*** (MNNG) 70-25-7
152 1475 .366mg 1.00mg 0/30 .366mg 10/30 1.52mg 20/30
a 1475 1.28mg n.s.s. 0/30 .366mg 0/30 1.52mg 0/30
3-METHYLCHOLANTHRENE*** 56-49-5
153 1484m .518mg n.s.s. 0/40 1.07mg 0/6
154 1484n 1.94mg n.s.s. 0/40 1.61mg 0/15
155 1484o 3.24mg n.s.s. 0/40 2.68mg 0/15
6-METHYLQUINOLINE 91-62-3
156 1529 52.6mg n.s.s. 3/44 25.0mg 5/37
157 1529 42.5mg n.s.s. 0/31 20.0mg 4/38
8-METHYLQUINOLINE 611-32-5
158 1529 175.mg n.s.s. 3/44 25.0mg 0/34
159 1529 78.3mg n.s.s. 0/31 20.0mg 0/19
2-NAPHTHYLAMINE*** 91-59-8
160 1564 21.2mg n.s.s. 0/20 24.4mg 4/18
2-NAPHTHYLAMINO,1*SULFONIC ACID 81-16-3
161 1488 942.mg n.s.s. 14/49 306.mg 15/48
a 1488 3.339m n.s.s. 1/49 306.mg 1/48
162 1488 765.mg n.s.s. 14/48 283.mg 16/47
a 1488 2.42gm n.s.s. 2/48 283.mg 2/47
NICOTINE.HCL 636-79-3
163 1530 834.mg n.s.s. 15/95 125.mg 6/46 188.mg 9/48
a 1530 1.06gm n.s.s. 0/99 125.mg 0/50 188.mg 0/48
164 1530 606.mg n.s.s. 2/62 104.mg 0/38 156.mg 0/32
a 1530 1.419m n.s.s. 22/88 104.mg 6/50 156.mg 6/48
NICOTINIC ACID 59-67-6
165 1530 5.50gm n.s.s. 15/95 2.00gm 13/48
a 1530 36.89m n.s.s. 0/99 2.009m 0/50
166 1530 7.84gm n.s.s. 22/88 1.67gm 9/50
a 1530 9.24gm n.s.s. 2/62 1.67gm 1/33
NITRATE, SODIUM*** 7631-99-4
167 1490 10.1gm n.s.s. 2/50 1.069m 0/50 2.119m 0/49
a 1490 2.99gm n.s.s. 46/50 1.06gm 43/50 2.11gm 39/49
168 1490 10.2gm n.s.s. 6/50 846.mg 7/50 1.69gm 4/50




















Spe Strain Site Xpo +Xpt
Sex Route Hist Notes
NITRITE, SODIUM-** 104
169 R f 134 wit Liv mix 24.28 a
a R f f34 wat tba mix 24.28 a
170 R m 134 wet Liv mix 24.28 a
a R m 134 wet tba mix 24.28 a
4-(5-NITRO-2-FURYL)THIAZOLE 104
171R ft I ad eat *gL fba 46w68 *
a ft f aid eat for sqc 46w68 a
b Rft masd eat Liv tum 46w68 a




Dng..:. .1ug...:.10 ...:.100... 1m,lg...-10 ...:.100...:.Ig . 10.:.I
.>no dre P-1. -
no dre P-1. -
.> ~~1.31gm * P<.5 -
noTD5O P-1. -






172 ft m f is eat ubL car 72w72 <+ noTD5O
6-NITRtOQUINOLINE lOOng. .:. .ug...:.10...:.100. 1.:mg...:.10...:.100.. g . 1
173Rft 1 34 eat Liv hnd 24.24 a .> no dre









175 ft f 134 sat for
a Rftff34.eat for
b Rft 1 34 eat Liv
176 ft m 134 sat for
a Rtm f34asat for














N-NITRtOSO-BIS-(4,4,4-TRtIFLUORtO.n-BUTYL)AMINE . 10 .I ...:.100..1m:.lg. 10 .I ...:.100... .Ig.10.:.I
177 Rft sda gay Liv hpc 7m23 .+ ..707mg
a Rft sda gay Lun mix 7m23 1.12mg
b Rft sda gay tba maL 7.23 .291mg
178 ft m sda gay Liv hpc 7.23 .+ ..793mg
a ft m ada gay Lun mix 7m23 .793mg
b ft m ida gav tba maL 7m23 .363mg
1-NITRtOSO.3,5-DIMETHYL-4-BENZOYLPIPERtAZINE. .lug... .10 ...:.100..1m:.lg... -10 ....100... -Ig ...:.10
179 Rft 1 34 wit for pam 12m29 a + .9.66mg
a Rft 1 34 wit Liv tum 12m29 a 9.10mg
b Rft 1 34 wit for bcc 12m29 a 26.4mg
c ft f f34 wit tba mix 12m29 a no dre
N-NITROSO.N-METHYL-N-DODECYLAMINE lOOng. .:. .lug... .10.... 100..1m:.lg... .10 ....100... .Ig ...:.10
180 ft m 134 gay ubL tcc 7m26 a + ..487mg
a Rtm f34 gav for car 7m26.o 5.07mg
b Rtm f34 gav --- Lou 7m26eo .970mg
c Rtm f34 gav pan isc 7m26. 2.75mg
d Rftmf34 gav Lun adc 7m26.o 6.54mg
a ft m 134 gay Liv hpc 7m26 a 8.98mg
fI fm f34 gav for pam 7m26.a 13.9mg
g Rtm f34 gav Lun ads 7m26.a 28.5mg
h Rtmf34 gav tba mix 7m26eo noTD5O
N-NITRtOSO-N-METHYL-N-TETRtADECYLANINE ..:. .lug...:.10 ...:.100.1m:.lg...:.10 ...:.100...:.Ig ...:.10
181 ft m 134 gay ubL tcc 7m24 a <+ noTD5O
a Rtm f34 gavLuna&de 7m24eo 29.4mg
b Rtm f34 gav Lun adc 7m24ea 60.5mg
c ft m 134 gay Liv tum 7m24 a no dre
































182 ft m 134 gay ubL tcc 7m24 a
a Rfml34 gav Lun adc 7m24a
b Rtm f34 gav Lun ado 7.24.o
c Rtm f34 gav Liv hpc 7m24.o
d Rtm f34 gav for pam 7m24.o
o fm f34 gav nasamix 7m24.o
fI fm f34 gavfor car 7m4eo
g Rtm f34 gav tba mix 7m24eo
NITRtOSOANYLURtETHAN
183 Rft don wit gao iqc 52w60 ao
a Rft don wit mix iqc 52w60 am
b Rft don wit *so pam 52w60 a.
c Rft don wit for pam 52w60 a.
d Rft don wat mix pam 52w60 a.
* ft don wit for iqc 52w60 a.
1 ft don wit tba mix 52w60 as
























.336mg * P<.0005SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
NITRITE, SODIUM*** 7632*00-0
169 1490 420.mg n.s.s. 1/49 51.0mg 0/48 85.0mg 0/48
a 1490 154..g n.s.s. 45/49 51.0mg 41/48 85.0mg 35/48
170 1490 306.mg n.s.s. 4/46 45.2mg 5/49 81.0mg 7/50
a 1490 n.s.s. n .s.. 46/46 45.2mg 49/49 81.0mg 50/50
4-(5-NITRO-2-FURYL)THIAZOLE 53757-28-1
171 1411 8.56mg 38.6mg 6/36 52.1mg 24/35
a 1411 11.2mg 38.0mg 0/36 52.1mg 19/35
b 1411 161.mg n.s.s. 0/36 52.1mg 0/35
c 1411 4.26mg 15.2mg 6/36 52.1mg 31/35
N-14-(5.NITRO-2.FURYL).2-THIAZOLYLJFORMAMIDE*** (FANFT) 24554-26.5
172 1430 n.s.s. 24.4mg 0/27 80.0mg 8/8
6-NITROQUINOLINE 613-50-3
173 1529 185.mg n.s.s. 3/44 25.0mg 0/36
174 1529 65.7mg n.s.s. 0/31 20.0mg 2/40
8-NITROQUINOLINE 607-35-2
175 1529 4.34mg 18.6mg
a 1529 19.6mg 59.5mg
b 1529 381.mg n.s.s.
176 1529 5.21mg 19.5mg
a 1529 14.2mg 48.3mg














177 1489 .382mg 1.47mg 0/24 1.35mg 17/24
a 1489 .576mg 2.55mg 0/24 1.35mg 13/24
b 1489 .120mg .693mg 4/24 1.35mg 23/24
178 1489 .425mg 1.68mg 0/24 1.35mg 16/24
a 1489 .425mg 1.68mg 0/24 1.35mg 16/24
b 1489 .176mg .788mg 2/24 1.35mg 22/24
I-NITROSO-3,5-DIMETHYL-4-BENZOYLPIPERAZINE
179 1208 3.65mg 111.mg 0/20 2.81mg
a 1208 3.31mg n.s.s. 1/20 2.81mg
b 1208 6.48mg n.s.s. 0/20 2.81mg
c 1208 .701mg n.s.a. 20/20 2.81mg
N-NITROSO-N-NETHYL-N-DODECYLANINE
180 1206 .200mg 1.12mg 0/20
a 1206 1.92mg 58.5mg 0/20
b 1206 .356mg n.s.s. 11/20
c 1206 1.11mg n.s.s. 3/20
d 1206 2.25mg n.s.s. 0/20
a 1206 2.71mg n.s.s. 0/20
f 1206 3.40mg n.s.s. 0/20
9 1206 4.63mg n.s.s. 0/20

















181 1206 n.s.s. 1.65mg 0/20 4.71mg 20/20
a 1206 7.23mg n.s.s. 0/20 4.71mg 2/20
b 1206 9.84mg n.s.s. 0/20 4.71mg 1/20
c 1206 18.7mg n.s.s. 0/20 4.71mg 0/20
d 1206 n.s.s. n.s.s. 19/20 4.71mg 20/20
N-NITROSO-N-NETHYLDECYLANINE 75881*22*0
182 1206 .630mg 2.73mg 0/20 3.63mg
a 1206 3.14mg 95.9mg 0/20 3.63mg
b 1206 4.45mg n.s.s. 0/20 3.63mg
c 1206 5.58mg n.s.s. 0/20 3.63mg
d 1206 7.59mg n.s.s. 0/20 3.63mg
* 1206 7.59mg n.s.s. 0/20 3.63mg
f 1206 7.59mg n.s.s. 0/20 3.63mg



















NITROSOANYLURETHAN (1-amyl -1-nitrosourethan) ---
183 1494 .664mg 1.63mg 0/37 2.86mg 19/29 5.71mg 17/29 (11.4mg 18/27)
a 1494 .769mg 1.59mg 0/37 2.86mg 19/29 5.71mg 21/29 11.4mg 21/27
b 1494 1.02mg 2.18mg 0/37 2.86mg 16/29 5.71mg 19/29 11.4mg 18/27
c 1494 .746mg 3.98mg 0/37 2.86mg 10/29 (5.71mg 3/29 11.4mg 2/27)
d 1494 1.05mg 3.02mg 0/37 2.86mg 11/29 5.71mg 14/29 (11.4mg 8/27)
* 1494 1.14mg 12.1mg 0/37 2.86mg 6/29 (5.71mg 1/29 11.4mg 0/27)
f 1494 .187mg .626mg 11/37 2.86mg 29/29 5.719g 29/29 11.4mg 26/27
Onodera;gann,73,48-54; 1982
181182 GOLD ET AL.
Spe Strain Site Xpo+Xpt TD50 ZTailpvl
Sex Route Hist Notes DR AuOp
N-NITROSOBIS(2-OXOPROPYL)ANINE l1Ong. ... lug.:10. :100. g : .g. :10. :100.:Ig. :10
184 R m mrw gav urt mix 24.24 . + .891mg P<.0005+
a R m mrw gav liv tur 24.24 1.56mg P<.002 +
b R m mrw gav ctr tur 24.24 1.56mg P<.002 +
c R m mrw gav nas tur 24.24 1.56mg P<.002 +
d R m mrw gav Lun tur 24r24 1.92mg P<.003 +
a R f mrw gav pro sqk 24.24 2.41mg P<.006 .
f R m rw gav thy tur 24m24 3.16mg P<.02 +
N-NITROSODIETHANOLANINE lOOng .. : lug.:10. :100. g : .1g :10. :100.. : . :10
185 R m ada wat Liv mix 27m34 ae . +. 8.23mg Z P<.0005+
a R m ada wat liv hpd 27m34 ae
b R m sda wat nas mix 27.34 ae
c R m sda wat nas olp 27m34 ae
d R m sda wat nas sqc 27.34 a.
a R f sda wat liv cgd 27m34 as
N-NITROSODINETHYLANINE***
186 N f cbL gav frb olp 50w72 a
a N f cbL gav Liv ben 50w72 a
b N f cbl gav Liv maL 50w72 a
c N f cbL gav Lun tur 50w72 a
d N f cbl gav tba rix 50w72 a
187 N m cbl gav frb oLp 50w72 a
a N m cbL gav Liv maL 50w72 a
b N m cbL gav Liv ben 50w72 a
c N m cbL gav Lun ads 50w72 a
d N m cbL gav tba mix 50w72 a




























188 R f don wat mix sqc 51w60 ae
a R f don wat for sqc 51w60 ae
b R f don wat mix pam 51w60 me
c R f don wat mso pam 51w60 ae
d R f don wat for pam 51w60 ae
a R f don wat eso sqc 51w60 ae
f R f don wat duo adc 51w60 as
g R f don wat tba mix 51w60 me










189 H f syg wat Liv hct 24m24
a H f syg wat tba mix 24.24
190 H m syg wat Liv hct 24r24
a H m syg wat Liv has 24m24
b H m syg wat tba mix 24m24
o-NITROSOTOLUENE
191 R m f34 sat Liv mix 72w93 a
a R m f34 sat ski fib 72w93 a
b R m f34 sat Liv hpt 72w93 a
c R m f34 sat ubL mix 72w93 a
d R m f34 sat ubL pam 72w93 a
a R m f34 sat spL fib 72w93 a
f R m f34 sat pec scs 72w93 a
g R m f34 sat pec mso 72w93 a
NORLESTRIN***
192 P f rho sat uts Ley 8ylO a
a P f rh, sat ski pam SylO a
b P f rhoeaat pdu ado 8ylO
c P f rho atLun tum 8ylO
d P f rho sat Liv tur BylO a
4,4' -OXYDIANILINE
193 N f b6c sat MXB NXB 24m24 s
a N f b6c sat hag adn 24m24 s
b N f b6c sat liv MXA 24r24 s
c N f b6c sat liv hpc 24m24 s
d N f b6c sat thy fca 24r24 s
a N f b6c sat liv hpa 24m24 s
f N f b6c sat TBA MXB 24r24 s
9 N f b6c sat Liv MXB 24.24 a
h N f b6c sat Lun NXB 24m24 s
194 N m b6c sat hag adn 24m24
a NM b6c sat --- h 24m24
b N a b6c eat pit adn 24m24
c N m b6c sat MXB MXB 24m24
d N m b6c sat Liv MXA 24m24
lOOng .. : ..ug.:10. :100. g :. . :10. :100..:1g :10
+ . 35.9mng * P<.008 +
8.44rg * P<.002
. + . 8.88mg * P<.0005+
130.mg * P<.2
9.26mg * P<.007

















lOOng..:. lug.:10. :100. g :. 1g :10. :100..: g. :10
.> 6.42rg * P<.2 -




lOOng. .:.l1ug.:10. :100. g :. 1g :10. :100.. : g :10
+ 19.7mg Z P<.002
46.8rg Z P<.0005c
108.mg * P<.0005c
252.rg * P<.01 c
598.rg * P<.0005c








225.mg * P<.5 c
* | .SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
N-NITROSOBIS(2-OXOPROPYL)AMINE 60599-38-4
184 1393 .411mg 2.36mg 0/15 1.43mg
a 1393 .658mg 5.63mg 0/15 1.43mg
b 1393 .658mg 5.63mg 0/15 1.43mg
c 1393 .658mg 5.63mg 0/15 1.43mg
d 1393 .770mg 9.22mg 0/15 1.43mg
a 1393 .907mg 22.8mg 0/15 1.43mg
f 1393 1.08mg n.s.s. 0/15 1.43mg
N-NITROSODIETHANOLAMINE 1116-54-7
185 1483 6.04mg 11.5mg 0/88 1.07mg
a 1483 6.94mg 13.3mg
b 1483 75.3mg 795.mg
c 1483 276.mg 4.62gm
d 1483 339.mg 11.0gm












186 1522 78.1ug .360mg 0/32 .238mg
a 1522 .143mg 1.82mg 0/32 .238mg
b 1522 .163mg 4.64mg 0/32 .238mg
c 1522 .706mg n.s.s. 0/32 .238mg
d 1522 46.8ug .441mg 8/32 .238mg
187 1522 82.3ug .377mg 0/38 .198mg
a 1522 89.3ug .440mg 0/38 .1989mg
b 1522 .161mg n.s.s. 2/38 .198mg
c 1522 .340mg n.s.s. 2/38 .198mg
d 1522 30.8ug .196mg 13/38 .198mg
Citation or Pathology
Brkly Code







7/72 4.29mg 43/72 17.9mg 33/36 (71.4mg 32/36 286.mg 31/36) Preussamnn;
cmnr,42,5167-5171;1982
5/72 4.29mg 40/72 17.9mg 32/36 (71.4mg 31/36 286.mg 31/36)
2/72 4.29mg 0/72 17.9mg 6/36 (71.4mg 6/36 286.mg 1/36)
1/72 4.29mg 0/72 17.9mg 4/36 71.4mg 3/36 (286.mg 0/36)
1/72 4.29mg 0/72 17.9mg 2/36 71.4mg 3/36 (286.mg 1/36)












188 1494 .108mg .260mg 0/37 .714mg 21/26 1.43mg 21/28 (2.86mg
a 1494 .170mg .375mg 0/37 .714mg 11/26 1.43mg 22/28 2.86mg
b 1494 .213mg .581mg 0/37 .714mg 14/26 1.43mg 14/28 (2.86mg
c 1494 .284mg .884mg 0/37 .714mg 11/26 1.43mg 11/28 (2.86mg
d 1494 .338mg .807mg 0/37 .714mg 6/26 1.43mg 16/28 2.86mg
1494 .317mg 1.08mg 0/37 .714mg 11/26 1.43mg 9/28 (2.86mg
f 1494 .364mg .900mg 0/37 .714mg 5/26 1.43mg 12/28 2.86mg











189 1503 12.4mg 770.mg 0/50
a 1503 4.27mg 39.7mg 3/50
190 1503 4.67mg 20.4mg 0/50
a 1503 21.2mg n.s.s. 0/50






0/30 2.18mg 1/30 4.50mg
2/30 2.18mg 10/30 4.50mg
1/30 1.92mg 2/30 3.96mg
0/30 1.92mg 0/30 3.96mg







191 1487 28.3mg 105.mg
a 1487 30.9mg 119.mg
b 1487 33.1mg 119.mg
c 1487 39.1mg 149.mg
d 1487 42.5mg 168.mg
1487 46.1mg 191.mg
f 1487 115.mg 8.01gm
9 1487 78.5mg n.s.s.
NORLESTRIN*** 8015-12-1
192 1441 1.05mg n.s.s.
a 1441 1.13mg n.s.s.
b 1441 1.86mg n.s.s.
c 1441 28.5ug n.s.s.



















































193 c50146 9.78mg 97.5mg 10/50
a c50146 27.4mg 135.mg 2/50
b c50146 58.1mg 413.mg 8/50
c c50146 115.mg 17.89m 4/50
d c50146 258.mg 2.04gm 0/50
* c50146 109.mg n.s.s. 4/50
f c50146 15.9mg 4.65gm 28/50
g c50146 58.1mg 413.mg 8/50
h c50146 58.4mg n.s.s. 5/50
194 c50146 14.2mg 73.2mg 1/50
a c50146 183.mg 2.05gm 0/50
b c50146 231.mg 4.96gm 1/50
c c50146 44.8mg n.s.s. 30/50















25/50 (38.3mg 23/50 102.mg
15/50 38.3mg 14/50 (102.mg
13/50 38.3mg 15/50 102.mg
7/50 38.3mg 6/50 102.mg
0/50 38.3mg 0/50 102.mg
6/50 38.3mg 9/50 102.mg
37/50 38.3mg 40/50 (102.mg
13/50 38.3mg 15/50 102.mg
5/50 38.3mg 10/50 (102.mg
17/50 (35.3mg 13/50 94.2mg
0/50 35.3mg 5/50 94.2mg
0/50 35.3mg 0/50 94.2mg
42/50 35.3mg 36/50 94.2mg





















183184 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
* N m b6c eat TBA MXB 24.24
f Mm b6c mat liv MXB 24.24
g N m b6c eat Lun MXB 24.24
195 R f f34 oat MXB MXB 24.24 s
a R f f34 mat thy MXA 24.24 s
b R f f34 eat Liv MXA 24.24 s
c R f f34 eat thy fca 24m24 s
d R f f34 eat Liv nnd 24.24 s
* R f f34 eat thy fcc 24.24 s
f R f f34 eat Liv hpc 24.24 s
g R f f34 oat TBA MXB 24.24 s
h R f f34 eat Liv MXB 24.24 s
196 R m f34 eat MXB MXB 24.24
a R m f34 eat Liv MXA 24.24
b R . f34 eat Liv hpc 24.24
c R m f34 eat thy MXA 24.24
d R m f34 mat Liv nnd 24.24
* R o f34 eat thy fcc 24.24
f R m f34 oat thy fca 24.24
g R f f34 eat TBA MXB 24.24
h R m f34 oat Liv MXB 24.24
PHENACETIN***
197 N f b6c mat lun ado 22m24 m
a N f b6c eat ubL pam 22m24 m
b N f b6c mat ubL tcc 22m24 m
c N f b6c mat Lun adc 22,24 a
d N f b6c mat Liv hnd 22m24 e
* N f b6c mat liv hem 22m24 e
f N f b6c eat Liv hpc 22m24 e
198 N m b6c eat kid rca 22m24 a
a N m b6c eat Lun adc 22m24 a
b N m b6c mat kid rcc 22m24 a
c N m b6c eat Lun ad. 22m24 e
d N m b6c eat Liv hpc 22m24 e
* N m b6c eat Liv hnd 22m24 a
f M m b6c eat Liv hem 22m24 a
PHENOBARBITAL***
199 N m b6c wat Liv mix 52w52 r
200 N m c5n wat Liv tum 78w78 r
201 N m con wat Liv mix 52w52 kr
202 N m can wat liv mix 52w52 r
PHENOL
203 N f b6c wat TBA MXB 24m24
a N f b6c wat Liv MXB 24,24
b N f b6c wat Lun MXB 24m24
204 N m b6c wat TBA MXB 24,24
a N m b6c wat Liv MXB 24m24
b N m b6c wat lun MXB 24m24
205 R f f34 wat TBA MXB 24,24
a R f f34 wat Liv MXB 24m24
206 R m f34 wat thy ccr 24m24
a R mf34 wat --- MXA 24m24
b R mf34 wat --- mLe 24m24
c R mf34 wat --- Ltu 24m24
d R m f34 wat TBA MXB 24m24
a R m f34 wat Liv MXB 24.24
PHENYL -beta-NAPHTHYLANINE***
207 R f ada gav Liv tum 32m32 a
a R f sda gav tba mix 32m32 a
208 R m sda gav Liv tum 37m37 a
a R m ada gav tba mix 37m37 a
I-PHENYLAZO-2.NAPHTHOL***
209 N f b6c aat .- - Lym 24m24
a N f b6c mat TBA NXB 24m24
b N f b6c mat Liv MXB 24m24
c N f b6c mat Lun MXB 24m24
210 N m b6c mat TBA MXB 24m24
a M m b6c mat Liv MXB 24m24
b M m b6c mat lun MXB 24m24
211 R f f34 mat Liv MXA 24m24
a R f f34 mat Liv nnd 24m24
b R f f34 mat sub fib 24m24
c R f f34 mat TBA MXB 24m24























7. 12mg Z P<.0005
bO0ng..:. .ug.:10. :100. g :. 1g :10. :100.. :g. :10
* 6.89gm * P<.1 -
37.0gm * P<.1 +
37.0gm * P<.1 +
8.83gm * P<.2 -
14.0gm * P<.3 -
29.2gm * P<.4 _
47.7gm * P<.7 _
+ . 1.109m * P<.0005+
3.80gm * P<.006 -
4.029m / P<.0005
5.28gm * P<.2 -
17.1gm \ P<.9 -
no dre P-I. -
no dre P-I. -









lOOng.. :. .ug.:10. :100. g :. 1g :10. :100.. : g. :10
:> no dre P-I.
no dre P-1.
18.59m P<.6
















lOOng .. : lug.:10. :100. g :..g :10. :100. I :g. :10




A 154.mg * P<.04 -
587.mg * P<.4
1.08gm * P<.5
+ 86.5mg * P<.01 c
96.6mg * P<.02 c
346.mg * P<.05
no dre P-1.
86.5mg * P<.01SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
c50146 50.1mg n.s.s.
f c50146 50.7mg n.s.s.
g c50146 381.mg n.s.s.
195 c50146 8.62mg 18.3mg
a c50146 10.2mg 20.8mg
b c50146 13.2mg 35.5mg
c c50146 18.1mg 44.4mg
d c50146 18.1mg 61.1mg
c50146 24.6mg 77.8mg
f c50146 45.6mg 260.mg
g c50146 9.60mg n.s.s.
h c50146 13.2mg 35.5mg
196 c50146 5.00mg 9.96mg
a c50146 5.38mg 10.3mg
b c50146 11.1mg 23.7mg
c c50146 12.2mg 30.1lg
d c50146 14.7mg 50.7mg
a c50146 20.6mg 63.2mg
f c50146 27.0mg 143.mg
g c50146 15.2mg n.s.s.
h c50146 5.38mg 10.3mg
PHENACETIN*** 62-44-2
197 1501 2.60gm n.s.s.
a 1501 9.10gm n.s.s.
b 1501 9.10gm n.s.s.
c 1501 3.23gm n.s.s.
d 1501 4.15gm n.s.s.
e 1501 6.97gm n.s.s.
f 1501 6.28gm n.s.s.
198 1501 754.mg 1.69gm
a 1501 1.90gm 41.0gm
b 1501 2.20gm 8.53gm
c 1501 1.87gm n.s.s.
d 1501 1.39gm n.s.s.
1501 4.58gm n.s.s.































































































































































































199 1477m n.s.s. 11.5mg 5/16 83.3mg 16/16
200 1477n 155.mg n.s.s. 0/16 83.3mg 0/16
201 1477o n.s.s. n.s.s. 5/8 83.3mg 8/8









203 c50124 1.71gm n.s.s.
a c50124 7.62gm n.s.s.
b c50124 3.60gm n.s.s.
204 c50124 1.48gm n.s.s.
a c50124 523.mg n.s.s.
b c50124 1.91gm n.s.s.
205 c50124 257.mg n.s.s.
a c50124 866.mg n.s.s.
206 c50124 158.mg 5.60gm
a c50124 57.0mg n.s.s.
b c50124 59.1mg n.s.s.
c c50124 59.1mg n.s.s.
d c50124 189.mg n.s.s.











































PHENYL-beta-NAPHTHYLAMINE*** (Agerite powder) 135-88-6
207 1524 2.429m n.s.s. 0/40 171.mg 0/40
a 1524 2.00gm n.s.s. 30/40 171.mg 3/40
208 1524 3.34gm n.s.s. 0/40 171.mg 0/40
a 1524 1.80gm n.s.s. 24/40 171.mg 8/40
1-PHENYLAZO-2-NAPHTHOL*** (C.I. Solvent YelLow 14) 842-07-9
209 c53929 55.6mg n.s.s. 9/50 63.8mg 23/50 (128.mg 17/50)
a c53929 96.1mg n.s.s. 28/50 63.8mg 34/50 128.mg 36/50
b c53929 279.mg n.s.s. 2/50 63.8mg 4/50 128.mg 6/50
c c53929 342.mg n.s.s. 3/50 63.8mg 6/50 128.mg 4/50
210 c53929 68.5mg n.s.s. 24/50 58.9mg 30/50 118.mg 37/50
a c53929 159.mg n.s.s. 15/50 58.9mg 11/50 118.mg 19/50
b c53929 250.mg n.s.s. 5/50 58.9mg 7/50 118.mg 7/50
211 c53929 40.2mg 4.20gm 2/50 12.4mg 3/49 24.8mg 11/50
a c53929 43.2mg n.s.s. 2/50 12.4mg 3/49 24.8mg 10/50
b c53929 104.mg n.s.s. 0/50 12.4mg 0/49 24.8mg 3/50
c c53929 24.4mg n.s.s. 44/50 12.4mg 41/49 24.8mg 38/50



















185186 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
212 R * f34 mat liv nnd 24.24
a R * f34 mat Liv NXA 24.24
b R * f34 mat TBA NXB 24.24
c R * f34 eat Liv NXB 24.24
PRAZIQUANTEL
213 H f syg gav tba mix 80w80 a
214 H m syg gav tba mix 80w80 a
215 R f sda gav tba mix 24.30 a







100ong. .... l:ug. 10. :100. 1m : g.:10. :100.. : g :10
.> 250.mg * P<.5
.> no dre P-1.
.> no dre P-I.
.> no dre P-1.
beta-PROPIOLACTONE*** l1Ong ..:. lug.:10. :100.:....:10. :100...:9 :10
217 R f ada gav sto tum 12m35 a . + . 1.61mg P<.0005+
PROPYL GALLATE
218 N f b6c mat liv hpa 24m24
a N f b6c mat TBA NXB 24.24
b N f b6c aat Liv NXB 24m24
c N f b6c mat lun NXB 24m24
219 N m b6c mat --- tyi 24m24
a Nm b6c eat - mLy 24m24
b Nm b6c mat --- lhc 24.24
c N a b6c mat TBA NXB 24.24
d N a b6c aat liv NXB 24m24
a N a b6c aat Lun NXB 24m24
220 R f f34 aat mgL ade 24m24
a R f f34 mat TBA NXB 24.24
b R f f34 mat Liv NXB 24m24
221 R a f34 mat pni isa 24.24
a R a f34 mat adr NXA 24m24
b R a f34 mat adr phe 24.24
c R a f34 mat pni NXA 24.24
d R m f34 mat pro NXA 24.24
a R f f34 mat thy NXA 24m24
f R a f34 mat TBA NXB 24m24
9 R m f34 mat liv NXB 24m24
lOOng . . .:ug.. : 10. :100.. :1.mg.. : 10. :100..g.10










#8.08gm a P<.05 -
no dre P-1.
no dra P-1.








1,2-PROPYLENE OXIDE 1 0Ong ..:. lug.:10. :100. g :. . :10. :100..:19 :10
222 R f ada gav sto mix 25m35 a . + . 39.5mg * P<.0005+
a R f ada gav for sqc 25m35 a 44.3mg * P<.0005+
QUERCETIN DIHYDRATE***
223 H f syg mat iLm adc 24m24
a H f syg mat for pam 24m24
224 H f syg mat for pam 23.23
a H f syg mat utm Lay 23m23
225 H f syg mat for pas 12.23
226 H a syg mat for pam 24m24
a H m syg mat adr coa 24m24
227 H a syg mat for pa. 23m23
a H m syg mat adr cos 23m23
228 H m syg mat for pam 12m23
QUILLAIA EXTRACT***
229 R f wis mat thy ada 25.25 a
a R f wis mat Liv ada 25m25 a
230 R a wis mat Liv ada 25m25 a
C.I. FOOD RED 3***
231 N f b6c mat TBA NXB 24m24
a N f b6c mat Liv NXB 24m24
b N f b6c mat Lun NXB 24m24
232 N a b6c mat TBA NXB 24m24
a N a b6c mat liv NXB 24m24
b N a b6c mat lun NXB 24m24
233 R f f34 mat uta msp 24.24
a R f f34 mat cLi saa 24m24
b R f f34 mat TBA NXB 24m24
c R f f34 mat Liv NXB 24m24
234 R a f34 mat TBA NXB 24.24
a R f f34 mat Liv NXB 24m24
D & C RED NO. 9***
235 N f b6c mat TBA NXB 24m24
a N f b6c mat Liv NXB 24m24
b N f b6c mat Lun NXB 24.24
236 N a b6c mat TBA NXB 24.24
a N a b6c mat Liv NXB 24.24
b N a b6c mat Lun NXB 24.24





















lOOng .. : ug. : 10. :100. la : g.:10. :100.. : g :10
*8.70g * P<.09 -
72.4gm * P<.2 -
no dre P-1.
lOOng .. : lug.:10. :100. 1m : g.:10. :100. : g. :10
:> no dre P-I.
no dre P-1.
no dre Pal.
:> no dra P-1.
no dre P-1.
no dra Pnl.




:> 1.86g. * P<.5 -
9.85gm * P<.7
lOOng .. : lug.:10. :100. g :. 1g :10. :100.:Ig. :10
:> 18.2gm * P<1. -
9.24gm P<.8
9.20gm P<.7
:> 2.12gm a P<.8 -
781.mg * P<.2
5.39g * P<.7SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
212 c53929 10.4mg 50.0mg 5/50 9.90mg 10/50 19.8mg 30/50
a c53929 10.3mg 55.3mg 6/50 9.90mg 10/50 19.8mg 31/50
b c53929 13.5mg n.s.s. 36/50 9.90mg 33/50 19.8mg 45/50
c c53929 10.3mg 55.3mg 6/50 9.90mg 10/50 19.8mg 31/50
PRAZIQUANTEL (Embay 8440, Droncit) 55268-74-1
213 1519. 50.3mg n.s.s. 12/99
214 1519. 79.5mg n.s.s. 23/99
215 1519n 57.7mg n.s.s. 76/97













217 1486 .986mg 2.65mg 0/50 2.86mg 46/50 Dunkelberg;bj ca,46,924-933; 1982
PROPYL GALLATE 121-79-9
218 c50588 3.56gm 370.gm
a c50588 2.54gm n.s.s.
b c50588 4.17gm n.s.s.
c c50588 6.71gm n.s.s.
219 c50588 2.92gm n.s.s.
a c50588 4.60gm n.s.a.
b c50588 5.22gm n. .s.
c c50588 604.mg n.s.s.
d c50588 4.54gm n.s.s.
a c50588 4.19gm n.s.s.
220 c50588 2.44gm n.s.s.
a c50588 663.mg n.s.s.
b c50588 n.s.s. n.s.s.
221 c50588 338.mg 2.74gm
a c50588 256.mg n.s.s.
b c50588 256.mg n.s.s.
c c50588 335.mg n.s.s.
d c50588 404.mg n.s.s.
a c50588 2.08gm n.s.s.
f c50588 581.mg n.s.s.

















































































222 1486 24.0mg 71.6mg 0/50
a 1486 26.3mg 82.6mg 0/50
QUERCETIN DIHYDRATE*** 6151-25-3
223 1144m 22.7gm n.s.s. 0/20
a 1144. 20.5gm n.s.s. 2/20
224 1144n 4.63gm n.s.s. 0/8
a 1144n 6.37gm n.s.s. 0/8
225 1144o 698.mg n.s.s. 0/8
226 1144m 12.6gm n.s.s. 1/20
a 1144m 18.0gm n.s.s. 2/20
227 1144n 10.7gm n.s.s. 1/8
a 1144n 12.2gm n.s.s. 1/8
228 11440 228.mg n.s.s. 1/8
Dunketberg;bj ca,46,924-933; 1982 3.13mg 2/50 12.5mg 21/50





















QUILLAIA EXTRACT*** (spray-dried aqueous extract of quiLtaia bark) ---
229 1527 3.06gm n.s.s. 0/39 150.mg 2/40 500.mg 5/45 1.509g 4/42
a 1527 11.8gm n.s.s. 0/42 150.mg 0/45 500.mg 0/46 1.50gm 1/46
230 1527 605.mg n.s.s. 0/40 120.mg 0/33 400.mg 0/26 1.20gm 0/44
Drake;fctx,20, 15-23;1982
C.I. FOOD RED 3*** (carmoisine, C.I. Acid Red 14, disodium saLt) 3567-69-9
231 c53849 1.45gm n.s.s. 28/50 386.mg 29/50 773.mg 23/49
a c53849 3.32gm n.s.s. 3/50 386.mg 5/50 773.mg 2/49
b c53849 2.93gm n.s.s. 4/50 386.mg 4/50 773.mg 4/49
232 c53849 680.mg n.s.s. 31/50 357.mg 28/50 713.mg 31/50
a c53849 1.28gm n.s.s. 15/50 357.mg 9/50 713.mg 14/50
b c53849 2.18gm n.s.s. 4/50 357.mg 4/50 713.mg 4/50
233 c53849 1.47gm n.s.s. 9/90 613.mg 11/50 1.239m 14/50
a c53849 4.96gm n.s.s. 0/90 613.mg 0/50 1.23gm 3/50
b c53849 1.01gm n.s.s. 68/90 613.mg 34/50 1.23gm 44/50
c c53849 9.34gm n.s.s. 3/90 613.mg 1/50 1.23gm 1/50
234 c53849 407.mg n.s.s. 61/90 238.mg 22/50 495.mg 34/50
a c53849 1.34gm n.s.s. 5/90 238.mg 3/50 495.mg 3/50
D & C RED NO. 9*** (briLliant red) 5160-02-1
235 c53792 319.mg n.s.s. 26/50 128.mg 25/50 255.mg 27/50
a c53792 803.mg n.s.s. 5/50 128.mg 3/50 255.mg 6/50
b c53792 1.139m n.s.s. 2/50 128.mg 1/50 255.mg 3/50
236 c53792 258.mg n.s.s. 23/50 118.mg 28/50 235.mg 24/50
a c53792 293.mg n.s.s. 8/50 118.mg 13/50 235.mg 15/50













S188 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
237 Rt f 34 sat liv nnd 24.24
a R f f34 eat TBA MXB 24.24
b R f f34 sat liv NXB 24.24
238 R m f34 eat NXB MXB 24.24
a R m f34 eat spt MXA 24.24
b R m f34 sat spL fba 24.24
c R m f34 sat liv nnd 24.24
d R m f34 sat spt ost 24.24
* R f f34 sat liv MXA 24.24
f R m f34 eat TBA MXB 24.24
9 R m f34 sat liv MXB 24.24
ROSANILINE.HCL***
239 R f sda gav Liv tum 25m25 *v
a R f ada gav tba mix 25m25 ev
240 R m ada gav Liv tum 26m26 av
a R m sda gav tba mix 26.26 *v
p-ROSANILINE.HCl***
241 R f sda gav Liv tum 29m29 ov
a R f ada gav tba mix 29m29 *v
242 R a sda gav Liv tum 29m29 *v
a R a sda gav tba mix 29m29 ev
RUTIN TRIHYDRATE***
243 H f syg aat adr coa 24m24
a H f syg aat uts lay 24m24
244 H a syg sat adr coa 24m24
a H m syg eat for pam 24m24
SACCHARIN, SODIUM***
245 R a f34 sat ubL tum 24m24 r
246 R m f34 aat ubl tum 24m24 r
247 R m fis aat ubl mix 23m24
SAFROLE***
248 N m bal sat Liv hpa 52w52 *k
a N m bal sat Liv hpc 52w52 *k
b N m bat sat Lun tum 52w52 *k
249 N a bal sat Liv hpa 52w75 ak
a N m bal oat Liv hpc 52w75 *k
b N a bat sat Lun tum 52w75 ak
STERIGMATOCYSTIN***
250 N f bd1 sat Liv has 55w68 *k
a N f bd1 sat Liv ang 55w68 ak
b N f bdl aat brf ang 55w68 *k
c N f bdl sat Liv hpa 55w68 *k
d N f bd1 sat Lun ado 55w68 *k
251 N f bdl eat Liv ang 55w73 a
a N f bdl sat Liv has 55w73 a
b N f bd1 sat brf ang 55w73 a
c N f bd1 sat Lun ads 55w73 a
d N f bdl sat Lun ang 55w73 a
a N f bdl oat Liv hpc 55w73 a
TARA GUM
252 N f b6c aat TBA MXB 24m24
a N f b6c sat Liv NXB 24m24
b N f b6c sat Lun MXB 24m24
253 N a b6c sat TBA NXB 24m24
a N m b6c sat Liv MXB 24m24
b N m b6c sat Lun MXB 24m24
254R f f34 sat TBA NXB 24m25
a R f f34 oat Liv NXB 24m25
255 Rf f34 sat TBA MXB 24m24
a R m f34 aat Liv MXB 24m24
TETRAFLUOROBORATE, SODIUM
256 H f syg gav Liv cho 70w70 es
a H f syg gav Lun tum 70w70 as
257 H m syg gav Liv hem 90w90 *s
a H m syg gav Lun tum 90w90 es
TIN (II) CHLORIDE***
258 N f b6c sat pit ads 24m24 ae
a N f b6c sat Liv hpc 24m24 as
b N f b6c sat - Lhc 24m24 ae
c N f b6c sat TBA NXB 24m24 ae
d N f b6c sat Liv NXB 24m24 as
TD50 2Tailpvl
DR AuOp






265.mg * P<.004 c
728.mg * P<.005 c
357.mg * P<.03 c
331.mg I P<.5
357.mg * P<.03






































































loong .. : lug.:10. :100. g :.1g :10. :100..:19 :10
no dre Pl. 1
no dre P-1.
no dre P-I.
:> 31.09m * P<.7 -
289.gm * P<1.
85.6gm * P<.8
5.03gm * P<.5 -
no dre P-1.
:> 93.3gm * P<. -
24.5gm * P<.4





bOOng .. : lug.:10. :100. g :.1g :10. :100.. : g :10




1.029m * P<.06SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl IDose lInc 2Dose 2Inc
237 c53792 386.mg n.s.s.
a c53792 149.mg n.s.s.
b c53792 386.mg n.s.s.
238 c53792 66.0mg 190.mg
a c53792 88.7mg 265.mg
b c53792 119.mg 425.mg
c c53792 140.mg 1.80gm
d c53792 276.mg 5.35gm
c53792 154.mg n.s.s.
f c53792 69.0mg n.s.s.

























































ROSANILINE.HCl*** (magenta I) 632-99-5
239 1524 266.mg n.s.s. 0/40 30.4mg 0/40
a 1524 210.mg n.s.s. 23/40 30.4mg 3/40
240 1524 285.mg n.s.s. 0/40 30.4mg 0/40









241 1524 597.mg n.s.s. 0/40 48.6mg 0/40
a 1524 244.mg n.s.s. 23/40 48.6mg 11/40
242 1524 571.mg n.s.s. 0/40 48.7mg 0/40
a 1524 201.mg n.s.s. 10/40 48.7mg 7/40
RUTIN TRIHYDRATE*** 153-18-4
243 1144 18.4gm n.s.s. 1/20
a 1144 22.7gm n.s.s. 0/20
244 1144 18.0gm n.s.s. 2/20
a 1144 22.7gm n.s.s. 1/20
SACCHARIN, SODIUM*** 128-44-9
245 1479m 8.49gm n.s.s. 0/37
246 1479n 8.66gm n.s.s. 0/37
247 1430 10.3gm n.s.s. 0/27
SAFROLE*** 94*59-7
248 1474m 27.1mg 234.mg 0/10
a 1474m 90.1mg n.s.s. 0/10
b 1474m 247.mg n.s.s. 0/10
249 1474n n.s.s. 164.mg 0/5
a 1474n 36.1mg n.s.s. 0/5
b 1474n 178.mg n.s.s. 0/5
STERIGMATOCYSTIN*** 10048-13-2
250 1492m .226mg 1.80mg 0/10
a 1492m .490mg 9.33mg 0/10
b 1492m 1.43mg n.s.s. 0/10
c 1492m 1.43mg n.s.s. 0/10
d 1492m 1.43mg n.s.s. 0/10
251 1492n .420mg 1.20mg 0/35
a 1492n 2.35mg 41.4mg 0/35
b 1492n 2.67mg 320.mg 0/35
c 1492n 3.08mg n.s.s. 0/35
d 1492n 6.06mg n.s.s. 0/35



















































252 c54364 10.4gm n.s.s.
a c54364 9.39gm n.s.s.
b c54364 38.2gm n.s.s.
253 c54364 5.09gm n.s.s.
a c54364 10.5gm n.s.s.
b c54364 10.5gm n.s.s.
254 c54364 1.19gm n.s.s.
a c54364 21.2gm n.s.s.
255 c54364 1.47gm n.s.s.
a c54364 6.14gm n.s.s.
TETRAFLUOROBORATE, SODIUM
256 1329 4.24mg n.s.s.
a 1329 4.24mg n.s.s.
257 1329 7.01mg n.s.s.











































TIN (II) CHLORIDE*** (stannous chLoride) 7772-99-8
258 c02722 564.mg n.s.s. 0/50 130.mg 4/50 258.mg 2/50
a c02722 574.mg n.s.s. 0/50 130.mg 3/50 258.mg 3/50
b c02722 871.mg n.s.s. 0/50 130.mg 0/50 258.mg 4/50
c c02722 150.mg n.s.s. 22/50 130.mg 32/50 258.mg 27/50





189190 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
* N f b6c sat Lun NXB 24.24 ae
259 N m b6c sat TBA MXB 24.24
a N m b6c sat Liv MXB 24.24
b N a b6c sat Lun MXB 24.24
260 R f f34 sat TBA MXB 24.24
a R f f34 sat Liv MXB 24.24
261 R a f34 sat thy MXA 24.24 as
a R m f34 sat thy ccr 24.24 ae
b R m f34 sat Lun a/a 24.24 as
c R m f34 sat TBA MXB 24.24 as
d R m f34 sat Liv MXB 24.24 ae
o-TOLUIDINE.HCL***
262 R m f34 sat ski fib 72w93 a
a R f134 sat mai fba 72w93 a
b R m f34 sat spL fib 72w93 a
c R a f34 sat pec scs 72w93 a
d R m f34 sat ubL mix 72w93 s
a R m f34 sat liv mix 72w93 a
L-TRYPTOPHAN***
263 R m fis sat ubL mix 23.24
VINYL CHLORIDE***
264 R m sda inh Liv hpc 12m30 s
a R m sda inh liv ang 12m30 a
b R m ada inh adr tum 12m30 a
c R m ads inh Liv mix 12m30 a
d R m sda inh pit tum 12m30 s
a R m sds inh tba mix 12m30 s
VINYLIDENE CHLORIDE***
265 N f b6c sat --- NXA 24m24
a N f b6c eat --- lym 24m24
b N f b6c sat TBA NXB 24m24
c N f b6c sat Liv MXB 24m24
d N f b6c sat Lun MXB 24m24
266 N a b6c sat TBA NXB 24m24
a N m b6c sat Liv NXB 24m24
b N m b6c sat lun MXB 24m24
267 R f f34 sat TBA NXB 24m24
a R f f34 sat Liv NXB 24m24
268 R m f34 sat TBA NXB 24m24
a R a f34 sat Liv MXB 24m24
C.I. DISPERSE YELLOW 3
269 N f b6c sat MXB NXB 24m24
a N f b6c sat Liv NXA 24m24
b N f b6c sat Liv hpa 24m24
c N f b6csat -- NXA 24m24
d N f b6c eat --- Lym 24m24
a N f b6c sat TBA NXB 24m24
f N f b6c sat Liv MXB 24m24
9 N f b6c sat Lun MXB 24m24
270 N m b6c sat Lun a/a 24m24
a N m b6c sat TBA MXB 24m24
b N m b6c sat Liv MXB 24m24
c N m b6c sat Lun MXB 24m24
271 R f f34 sat TBA NXB 24m24
a R f f34 sat Liv MXB 24m24
272 R m f34 sat NXB NXB 24m24
a R a f34 sat Liv nnd 24m24
b R m f34 sat Liv MXA 24m24
c R m f34sat sto --- 24m24
d R a f34 sat TBA NXB 24m24
a R a f34 sat Liv NXB 24m24
FD £ C YELLOW NO. 6***
273 N f b6c sat TBA MXB 24m24
a N f b6c sat Liv NXB 24m24
b N f b6c sat Lun NXB 24m24
274 N m b6c sat ski MXA 24m24
a N m b6c sat TBA MXB 24m24
b N a b6c sat Liv NXB 24m24
c N m b6c sat lun NXB 24m24
275 R f f34 sat TBA MXB 24m24
a R f f34 sat Liv NXB 24.24
276 R m f34 sat TBA NXB 24m24




no dre P-I. -
no dre P-1.
no dre P-1.
12.09m * P<1. -
676.gm * P<1.





bO0ng. . .. :1ug. 10. :100. la : g.:10..:100.. : . :10












lOOng. . . : lug. 10. :100. 1m :.g.: 10. :100.:1 . :.10
.> no dre P-I.
lOOng. . .. : lug. 10. :100. 1m : g.:10. :100.. : g :10












lOOng .. : lug.:10. :100. g :. 1g :10. :100.:Ig. :10












bO0ng .. : lug.:10. :100. g :. 1g :10. :100.. : g :10












no dre P-1. -
46.8gm * P<.9
+ 330.mg \ P<.003
380.mg \ P<.003 c
833.mg * P<.04 c
+historical * P<.4 a
no dre Pal.
833.mg * P<.04
lOOng.. : .ug.:10. :100. g : ..g :10. :100.. : g :10
:>no dre P-1. -
no dre P-1.
66.4gm * P<.3




9.06gm * P<.8 -
no dre P-1.
11.8gm * P<.9 -
2.52gm \ P<.08
: +SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl
c02722 1.069m n.s.s.
259 c02722 373.mg n.s.s.
a c02722 655.mg n.s.s.
b c02722 671.mg n.s.s.
260 c02722 87.0mg n.s.s.
a c02722 891.mg n.s.s.
261 c02722 41.4mg 628.mg
a c02722 174.mg n.s.s.
b c02722 287.mg n.s.s.
c c02722 49.0mg n.s.s.

























































262 1487 21.8mg 74.2mg 1/27
a 1487 74.0mg 372.mg 0/27
b 1487 81.0mg 452.mg 0/27
c 1487 89.2mg 571.mg 0/27
d 1487 164.mg n.s.s. 0/27
1487 212.mg n.s.s. 1/27
L -TRYPTOPHAN*** 73-22-3
263 1430 4.12gm n.s.s. 0/27
VINYL CHLORIDE*** 75-01-4
264 1440 26.7mg 67.3mg 1/80
a 1440 51.7mg 177.mg 0/80
b 1440 108.mg 1.09gm 0/80
c 1440 120.mg 1.93gm 0/80
d 1440 61.0mg n.s.s. 8/80























265 c54262 1.54mg n.s.s. 7/50
a c54262 1.65mg n.s.s. 2/50
b c54262 .838mg n.s.s. 23/50
c c54262 28.7mg n.s.s. 4/50
d c54262 19.2mg n.s.s. 1/50
266 c54262 6.01mg n.s.s. 30/50
a c54262 11.1mg n.s.s. 15/50
b c54262 12.8mg n.s.s. 5/50
267 c54262 3.65mg n.s.s. 42/50
a c54262 31.4mg n.s.s. 4/50
268 c54262 2.81mg n.s.s. 29/50
a c54262 10.1mg n.s.s. 1/50
C.I. DISPERSE YELLOW 3 2832-40-8
269 c53781 385.mg 3.96gm 12/50
a c53781 590.mg 3.05gm 2/50
b c53781 769.mg 2.96gm 0/50
c c53781 654.mg n.s.s. 10/50
d c53781 689.mg n.s.s. 10/50
a c53781 362.mg n.s.s. 20/50
f c53781 590.mg 3.05gm 2/50
g c53781 3.62gm n.s.s. 6/50
270 c53781 960.mg n.s.s. 2/50
a c53781 624.mg n.s.s. 33/50
b c53781 1.31gm n.s.s. 20/50
c c53781 977.mg n.s.s. 3/50
271 c53781 232.mg n.s.s. 38/50
a c53781 2.42gm n.s.s. 2/50
272 c53781 170.mg 1.87gm 2/50
a c53781 196.mg 1.80gm 1/50
b c53781 397.mg n.s.s. 2/50
c c53781 1.41gm n.s.s. 0/50
d c53781 569.mg n.s.s. 37/50
c53781 397.mg n.s.s. 2/50
1.43mg 15/50 (7.14mg 7/50)
1.43mg 9/50 (7.14mg 6/50)
1.43mg 33/50 (7.14mg 21/50)
1.43mg 3/50 7.14mg 3/50
1.43mg 1/50 7.14mg 4/50
1.43mg 22/50 7.14mg 33/50
1.43mg 9/50 7.14mg 15/50
1.43mg 5/50 7.14mg 8/50
.714mg 38/50 3.57mg 36/50
.714mg 0/50 3.57mg 0/50
.714mg 25/50 3.57mg 43/50









* t- :lym; liv:hpa,hpc. T
liv:hpa,hpc.
---:lau,Lym. S
319.mg 25/50 638.mg 31/50
319.mg 10/50 638.mg 17/50
319.mg 6/50 638.mg 12/50
319.mg 17/50 638.mg 20/50
319.mg 16/50 638.mg 19/50
319.mg 33/50 638.mg 36/50
319.mg 10/50 638.mg 17/50
319.mg 0/50 638.mg 4/50
294.mg 6/50 589.mg 9/50
294.mg 26/50 589.mg 33/50
294.mg 12/50 589.mg 16/50
294.mg 7/50 589.mg 9/50
248.mg 40/50 (495.mg 25/50)
248.mg 1/50 495.mg 3/50
198.mg 18/50 (396.mg 11/50)
198.mg 15/50 (396.mg 10/50)
198.mg 15/50 396.mg 11/50
198.mg 3/50 396.mg 1/50
198.mg 37/50 396.mg 32/50










FD 8 C YELLOW NO. 6*** (sunset yeaLow FCF) 2783-94-0
273 c53907 7.16gm n.s.s. 28/50 1.61gm 20/50 3.22gm 21/50
a c53907 15.8gm n.s.s. 7/50 1.61gm 3/50 3.22gm 4/50
b c53907 16.3gm n.s.s. 0/50 1.619m 1/50 3.22gm 1/50
274 c53907 11.3gm n.s.a. 0/50 1.49gm 0/49 2.97gm 3/50
a c53907 2.42gm n.s.s. 32/50 1.49gm 31/49 2.97gm 34/50
b c53907 3.04gm n.s.s. 13/50 1.49gm 23/49 2.97gm 16/50
c c53907 13.3gm n.s.s. 6/50 1.49gm 4/49 2.97gm 3/50
275 c53907 1.03gm n.s.s. 68/90 619.mg 37/50 1.24gm 42/50
a c53907 8.31gm n.s.s. 3/90 619.mg 3/50 1.24gm 0/50
276 c53907 973.mg n.s.s. 61/90 495.mg 34/50 990.mg 35/50








191192 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist No
ZEARALENONE
277 N f b6c sat MXB NXB 24.24
a N f b6c eat pit MXA 24.24
b N f b6c eat pit adn 24.24
c N f b6c eat liv hpa 24.24
d N f b6c eat liv MXA 24.24
a N f b6c sat TBA MXB 24.24
f N f b6c eat Liv MXB 24.24
9 N f b6c eat lun MXB 24.24
278 N m b6c sat pit MXA 24.24
a M m b6c eat pit ad. 24.24
b N m b6c eat TBA MXB 24.24
c N m b6c eat liv MXB 24.24
d N m b6c eat Lun MXB 24.24
279 R f f34 eat TSA MXB 24.24
a R f f34 eat liv MXB 24.24
280 R m f34 eat TBA MXB 24.24




lOOng .. : ug. : 10. :100.1 : g :. 100.. g . : 1 g :.10
+ 22.0mg * P<.003
32.3mg / P<.002 c
37.4mg P<.006 c
50.1mg P<.002 c









80.9mg * P<1. -
33.5mg * P<.1
16.2mg * P<.8 -
950.Mg * P<1.SUPPLEMENT TO CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
ZEARALENONE 17924-92-4
277 c50226 11.4mg 121.mg
a c50226 16.1mg 165.mg
b c50226 17.6mg 442.mg
c c50226 23.5mg 194.mg
d c50226 17.2mg n.s.s.
a c50226 7.55mg n.a.s.
f c50226 17.2mg n.s.s.
g c50226 59.5mg n.s.s.
278 c50226 24.6mg 383.mg
a c50226 26.0mg 417..g
b c50226 10.6mg n.s.s.
c c50226 25.9mg n.s.s.
d c50226 28.9mg n.a.s.
279 c50226 2.26mg n.s.s.
a c50226 10.2mg n.s.s.
280 c50226 1.71mg n.s.s.




































































































50-32-8 BENZPYRENE (see BENZO(a)PYRENE)




5160-02-1 BRILLIANT RED (see D & C RED NO. 9)






3567-69-9 CARMOISINE (see C.I. FOOD RED 3)





PYRAZINE(2,1-a) ISOQUINOLINE-4-ONE (see PRAZIQUANTEL)
16170-75-5 CYTEMBENA
538-41-0 DAAB (see 4,4'-DIAMINOAZOBENZENE)
785-30-8 DABA (see 4,4'-DIAMINOBENZANILIDE)








123-33-1 1,2-DIHYDRO-3,6-PYRIDAZINEDIONE (see MALEIC HYDRAZIDE)
25812-30-0 2,2-DIMETHYL-5-(2,5-XYLYLOXY)VALERIC ACID
(see GEMFIBROZIL)
62-75-9 DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
62-75-9 N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
62-75-9 DMN (see N-NITROSODIMETHYLAMINE)








24554-26-5 FANFT (see N-14-(5-NITRO-2-FURYL)-2-THIAZOLYLIFORMAMIDE)
2164-17-2 FLUOMETURON
53-96-3 FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)






9000-01-5 GUM ACACIA (see GUM ARABIC)
9000-01-5 GUM ARABIC
10034-93-2 HYDRAZINE SULFATE
119-53-9 2-HYDROXY-1,2-DIPHENYLETHANONE (see BENZOIN)
148-24-3 8-HYDROXYQUINOLINE
54-85-3 INH (see ISONLAZID)
54-85-3 ISONL4ZID
54-85-3 ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)
80-05-7 4,4'-ISOPROPYLIDENEDIPHENOL (see BISPHENOL A)
CAS
NUMBER CHEMICAL NAME
9000-40-2 LOCUST BEAN GUM
632-99-5 MAGENTA I (see ROSANILINE.HCI)








27323-65-5 METHYL LINOLEATE HYDROPEROXIDE
--- METHYL LINOLEATE, NATIVE
70-25-7 N-METHYL-N'-NITRO-N-NITROSOGUANIDINE




70-25-7 MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
91-59-8 2-NAPHTHYLAMINE
91-59-8 beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)
81-16-3 2-NAPHTHYLAMINO,1-SULFONIC ACID



















55090-44-3 NITROSOMETHYL-N-DODECYLAMINE (see N-NITROSO-N-
METHYL-N-DODECYLAMINE)


















3567-69-9 C.I. ACID RED 14, DISODIUM SALT (see C.I. FOOD RED 3)
3567-69-9 C.I. FOOD RED 3
5160-02-1 D & C RED NO. 9
632-99-5 ROSANILINE.HCI
569-61-9 p-ROSANILINE.HCI




7631-99-4 SODIUM NITRATE (see NITRATE, SODIUM)
13755-29-8 SODIUM TETRAFLUOROBORATE (see TETRAFLUOROBORATE,
SODIUM)
7772-99-8 STANNOUS CHLORIDE (see TIN (II) CHLORIDE)
10048-13-2 STERIGMATOCYSTIN
77-83-8 STRAWBERRY ALDEHYDE (see ETHYL
METHYLPHENYLGLYCIDATE)
2783-94-0 SUNSET YELLOW FCF (see FD & C YELLOW NO. 6)





7772-99-8 TIN (II) CHLORIDE






























80-05-7 BISPHENOL A (4,4'-isopropylidenediphenol)
81-16-3 2-NAPHTHYLAMINO,1-SULFONIC ACID














123-33-1 MALEIC HYDRAZIDE (1,2-dihydro-3,6-pyridazinedione)
127-06-0 ACETOXIME
128-37-0 BUTYLATED HYDROXYTOLUENE (BHT)
128-44-9 SACCHARIN, SODIUM


























2832-40-8 C.I. DISPERSE YELLOW 3
842-07-9 C.I. SOLVENT YELLOW 14 (see 1-PHENYLAZO-2-NAPHTHOL)
2783-94-0 FD & C YELLOW NO. 6
17924-92-4 ZEARALENONE







2783-94-0 FD & C YELLOW NO. 6 (sunset yellow FCF)
2832-40-8 C.I. DISPERSE YELLOW 3
3544-23-8 3-METHOXY-4-AMINOAZOBENZENE
3567-69-9 C.I. FOOD RED 3 (carmoisine, C.I. Acid Red 14, disodium salt)
6151-25-3 QUERCETIN DIHYDRATE
5160-02-1 D & C RED NO. 9 (brilliant red)
7631-99-4 NITRATE, SODIUM
7632-00-0 NITRITE, SODIUM
7772-99-8 TIN (II) CHLORIDE (stannous chloride)
8015-12-1 NORLESTRIN
9000-01-5 GUM ARABIC (gum acacia)
9000-30-0 GUAR GUM













25013-16-5 BUTYLATED HYDROXYANISOLE (BHA)
25812-30-0 GEMFIBROZIL














--- DEXTRAN SULFATE SODIUM (DS-M-1) (DS-M-1, MW-54,000)
--- METHYL LINOLEATE, NATIVE
--- N-NITROSO-BIS-(4,4,4-TRIFLUORO-n-BUTYL)AMINE
--- NITROSOAMYLURETHAN (1-amyl-1-nitrosourethan)
--- QUILLAIA EXTRACT (spray-dried aqueous extract ofquillaia bark)
CAS NUMBER - Chemical Abstracts Service registry number



















Code Strain Code Site
cb6 C57BL/6 eso esophagus
cbl C57BL for forestomach
cbn C57BL/6JfC3Hf/Nctr X BALB/cStCrlfC3Hf/Nctr inter se frb forebrain
cdl Charles River CD1 git gastrointestinal tract
cdr Charles River CD hag Harderian gland
cen C3H/HeN ilm ileum
cff C57BL/6JfC3Hf/Nctr X BALB/cStCrlfC3Hf/Nctr itn intestine
don Donryu k/c kidney/cortex
f34 Fischer 344 kid kidney
fis Fischer liv liver
lee Leeds albino lun lung
mrw MRC-Wistar mam mammary tissue (oth
rhe Rhesus [Macaca mulatta] mammary gland)
sda Sprague-Dawley mgl mammary gland
swa Swiss albino mix more than one site; si
swi Swiss mul multiple organs
syg Syrian Golden MXA more than one site, c
wis Wistar MXB more than one site, c
APPENDIX 4: ROUTE OF ADMINISTRATION
CODES AND DEFINITIONS










ier than or including more than
iites specified in published paper
ombined by NCI/NTP
sombined by Berkeley
gav gavage pro prostate
inh inhalation res respiratory system
wat water ski skin
spl spleen
- stg stomach, glandular APPENDIX 5: SITE CODES AND DEFINITIONS sto stomach
sub subcutaneous tissue
Code Site tba all tumor bearing animals
--- all target sites tes testis
abc abdominal cavity thy thyroid gland
adr adrenal gland tnv tunica vaginalis
brf brown fat, dorsal ubl urinary bladder




























cma c-cell medullary adenoma
coa cortical adenoma
crc chromophobe carcinoma






























mix more than one tumor type;





MXA more than one tumor type,
combined by NCI/NTP




APPENDIX 7: NOTECODES AND DEFINITIONS
Code Definition
a The exposure time reported on the plot is an average of
the different exposure times of the individual dose
groups in the experiment. In addition, for NCI/NTP
bioassays an "a" may indicate that all animals in one
group were dead long before those in another group, and
therefore the experiment time on the plot is an average
of experiment times for the different dose groups. (In
the TD50 calculation for the NCI/NTP bioassays, full
lifetable data have been used.)
e For the general literature we have used an effective
number of animals in a group whenever possible. This
effective number is either: (1) the number of animals
examined, or (2) the number of animals alive at the
time of appearance of the first tumor. For some
NCI/NTP bioassays the Technical Report includes
both time-adjusted and unadjusted statistical analyses.
Effective number indicates that some sites in these
experiments have been included in the plot on the basis
of the time-adjusted analysis.
k For interim and serial sacrifice experiments, we have
reported each sacrifice time as a separate experiment.
The k notecode identifies these sacrificed groups.
Unscheduled deaths have been included with the termi-
nal sacrifice data, wherever possible and do not receive
a notecode.
r Authors either examined or chose to report data for
only a few selected tissues. Therefore, this is a res-
tricted site analysis.
s Authors noted that survival was decreased due to toxi-
city or disease.
v Variable or irregular dosing schedules have been used,




































tumor or more than one tumor type;
tumor types not specified in published paper
undifferentiated leukemia
'NOS = not otherwise specified
APPENDIX 8: DOSE-RESPONSE CURVE
SYMBOLS AND DEFINITIONS
Symbol Dose-Response Curve
* consistent with linearity
/ significant departure from linearity, upward curvature
significant departure from linearity, downward curvature
Z significant departure from linearity, more than three dose
groups including controls
blank either no dose related effect, or only two dose groups
including controls, so not enough information to
determine a curve shape
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Cancer Institute. Journal)
Journal ofToxicology and Environmental Health
Mycopathologia
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Oncology
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Code Research
txcy Toxicology
zkko Journal of Cancer Research and Clinical Oncology (formerly
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prior to Vol 92, 1979)
APPENDIX 10:
NCI/NTP BIOASSAYS EVALUATED
AS INADEQUATE IN TECHNICAL REPORTS
Chemical Name Experiments Evaluated
as Inadequate
BUTYL BENZYL PHTHALATE male rats
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